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Since studies by Waddington and others in the 1950s it has been widely accepted that
strictly Mendelian inheritance is only observed for a minority of mutations. They
showed that large amounts of silent genetic variation exists in populations, which can
be revealed by changes in the environment or genetic background and dramatically
affect the developmental outcomes of mutations. Many human developmental
disorders, such as neural tube defects and Microphthalmia, Anophthalmia, and
Coloboma (MAC) seem to occur sporadically, but recurrence in families suggests
that genetic factors play an important role. Mutations have been identified in some of
these families, but the evidence suggests that multiple genetic and environmental
factors are important in others for determining the phenotypic outcome.
Recent work in Drosophila and Arabidopsis has shown that the chaperone protein
Hsp90 may have a role in the interaction between genetic and environmental factors
during development. A model has been proposed in which Hsp90 suppresses or
buffers silent variation under normal conditions, which is only expressed when
damaged proteins sequester Hsp90 during environmental stress. Hsp90 structure and
function is highly conserved in all organisms studied, and we hypothesised that this
buffering mechanism may play an important part in the aetiology of human
developmental disease. I conducted studies with zebrafish mutants and
pharmacological inhibitors of Hsp90 to determine whether the penetrance or
expressivity of the mutant phenotype could be altered.
Zebrafish embryos were treated with low levels of the specific Hsp90 inhibitors,
radicicol and geldanamycin. At the concentrations used, a heat shock response was
not observed at the protein or RNA level. Homozygotes for the recessive mutations
sunrise (sri) and dreumes (dre) were treated with radicicol, and the severity of the
phenotype was increased in sri and marginally decreased in dreumes, with respect to
control embryos from the same clutch. This effect was also observed with heat
shock. Geldanamycin also increased the severity of the sunrise phenotype, but an
analogue geldampicin that does not bind Hsp90 had no effect. It can be concluded
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from this that Hsp90 can buffer developmental defects in a vertebrate species when a
pathway is destabilised by a mutation.
The sri mutation was mapped in collaboration with Ralf Dahm and colleagues,
Tubingen. A missense mutation was identified in the homeodomain of Pax6b that
causes an L to P amino acid change. This is predicted to alter the structure or stability
of the Pax6b protein. Antisense oligonucleotide knockdown of Pax6b and/or Pax6a
function does not phenocopy sri, showing that it is not a full loss of function
mutation. Preliminary results suggest that injection of WT Pax6b mRNA rescues the
sri phenotype, confirming that the mutation identified in Pax6b causes the sri
phenotype. Pax6b is expressed in the pancreatic islet of WT embryos, and in sri the
pancreatic islet is severely disorganised, further confirming the causative nature of
the Pax6b mutation.
This study demonstrates the buffering properties of Hsp90 in a vertebrate system.
Pax6 mutant phenotypes in mammals are notoriously variable, and the fact that the
mutation buffered here is in Pax6, in addition to the well documented structural and
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1.1 Non-Mendelian inheritance of developmental eye defects
There are many familial developmental disorders that do not appear to be inherited in a
straightforward Mendelian fashion, such as cleft lip and palate, holoprosencephaly
(HPE), and neural tube defects. These often have a heterogeneous genetic component,
with causative mutations in different genes. For example, HPE can be caused by
mutations in SHH (Sonic hedgehog), TG1F (TG interacting factor), SIX3 (Sine oculis
homeobox 3) and ZIC2 (Zinc finger protein of cerebellum 2), among others (Reviewed
in Wallis and Meunke, 2000). In some cases oligogenic inheritance seems likely, as
mutations have been identified in some affected individuals, but also in unaffected
carriers. There are several examples of this among the eye disorders, in which the
disease allele is dominant, but does not have full penetrance. Genetic modifiers and
environmental factors almost certainly play an important role in the aetiology of these
diseases.
MAC is a developmental disorder characterised by a spectrum of structural eye defects:
reduced eye size (Microphthalmia), absence of the eye (Anophthalmia), or non closure
of the optic fissure (Coloboma) (Morrison et al. 2002). Study of the genetic basis of
MAC has shown it to be a good example of a non-Mendelian, genetically heterogeneous
disorder that may be susceptible to environmental effects. Causative mutations have
been identified in genes as diverse as Pax2 (Paired box gene 2) (Cunliffe et al. 1998),
SOX2 (SRY box 2) (Fantes et al. 2003), CHX10 (CHEH10 hox-containing homolog)
(Ferda Percin et al. 2000), SIX3 (Wallis et al. 1999), and SHH (Schimmenti et al. 2003).
In some families with recurrent cases of MAC, a single causative mutation has been
identified, with a straightforward dominant inheritance pattern (Ferda Percin et al. 2000,
Fantes et al. 2003). In other cases unaffected or extremely mildly affected individuals
carry the same mutation as the very severely affected. This suggests that other genetic or
environmental factors are important in the aetiology of the disease (Amiel et al. 2000,
Schimmenti et al. 2003). Unilateral malformations often occur, as well as variable
severity in each eye for individuals with bilateral defects (Fantes et al. 2003, Wallis et
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al. 1999). This is direct evidence for the importance of environmental factors as well as,
or in addition to, stochastic events (Reviewed in McAdams and Arkin, 1999) in the
aetiology of these defects.
Clusters of MAC cases in rural areas of the UK were reported by the Observer in 1993,
with an alleged link to the teratogenic pesticide Benomyl, leading to significant media
interest (Pesticides News, 1997). Teratogens are defined as substances that disrupt
normal development (Lawrence, 2000). These pass through the placenta, and can cause
intrauterine growth retardation (IUGR), or specific effects on certain organs during
especially sensitive periods (Figure 1.1). An epidemiological study of congenital eye
malformations in Spain showed that teratogenic effects could account for a high
proportion (over 10%) of cases (Bermejo and Martinez-Frias 1998). Suspected
teratogens for cases identified in India included agricultural chemicals, abortifacients,
vitamin A deficiency, and drug usage (Hornby et al. 2002). Also, a recent letter to the
Guardian from the chief medical officer to the Gulf war veterans reported an unusually
high incidence of anophthalmia in children born in Iraq following the Gulf war,
suggesting that this was linked to pollution of the environment as a consequence of the
fighting (Hooper, 2002).
Although virtually any chemical can have a teratogenic effect at a high enough dose,
some chemicals have a more powerful effect on development. The dose of benomyl
required to cause eye defects is so high that that a link between pesticide use and MAC
seemed unlikely (Pesticides news, 1997). Also a study of anophthalmia and
microphthalmia incidence in the UK did not find enough statistical evidence for the
clusters reported by the media, as the numbers of affected individuals are so low
(Cuzick, 1998, Dolk et al. 1998). Some individuals may however carry genetic factors
that increase their sensitivity to a teratogen. In the case of benomyl, it may only be
individuals at a vulnerable stage of development, and carrying particular genetic factors
that are affected, giving the low numbers of cases reported.
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Figure 1.1: Sensitive periods of embryogenesis. (a) Organ-specific
periods of sensitivity (Reproduced from Moore, 1998); (b) Overall sensitivity
to teratogens peaks at approximately day 5 of embryogenesis (Reproduced
from Sadler, 2003).
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1.2 Hsp90 as a buffer of developmental defects
Studies of genetic disorders in animal models have shown that Mendelian inheritance
can be altered on different genetic backgrounds. Waddington showed that a large
amount of hidden or "cryptic" genetic variation exists in wild type (WT) Drosophila
populations, which can be uncovered by environmental changes. The morphological
defects that appeared after a heat shock during development, such as loss of cross veins
in the wing, could be selected for over successive rounds of breeding and heat shock,
until the traits were independent of heat shock (Reviewed in Scharloo, 1991, Rutherford,
2000). This demonstrated that genetic variation for the trait under selection existed in the
original population, and was revealed by environmental disturbance. Waddington
described the invariance, or robustness of developmental pathways to environmental or
genetic disturbance as canalisation, or buffering (Waddington, 1942).
Rutherford and Lindquist (1998) took Waddington's experiments a step further when
they observed that Drosophila carrying mutations in Heat Shock Protein 83 (Hsp83, or
Hsp90) mutant stocks showed an unusually high rate of morphological defects. Hsp90 is
a molecular chaperone with a role in stabilising signalling proteins important in
development, as well as a more general role in assisting the folding or degradation of
proteins damaged by denaturing conditions (Reviewed in Mayer and Bukau, 1999). It
was shown that when Hsp83 mutant strains were outcrossed to different WT strains,
defects arose that were specific to each strain. These results were replicated when
geldanamycin was used to compromise Hsp83 function. The morphological defects that
were revealed could be selected for, so that the traits became independent of the Hsp83
mutation. Variation for these traits therefore existed in the original populations, as found
by Waddington in his heat shock experiments. The traits selected for by Rutherford and
Lindquist were also enhanced at higher temperatures. They proposed a mechanism
whereby Hsp90 is important in stabilising many developmental signalling proteins. If
Hsp90 function is compromised, or sequestered by general protein damage, these signals
are weakened. The simultaneous weakening of several signals important to the same
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developmental process can have a major effect on the morphological outcome. The most
vulnerable developmental pathways are those that contain cryptic genetic variation, and
over many rounds of selection these mutations can accumulate and overcome the
buffering effect of Hsp90 on the trait of interest (Rutherford and Lindquist, 1998, Figure
1.2).
Further work in Arabidopsis has confirmed these findings, and demonstrated that Hsp90
can buffer potentially useful traits (Queitsch et al. 2002). The conclusions drawn from
these studies were that Hsp90 can therefore be viewed as an "evolutionary capacitor"
that allows the accumulation of hidden genetic variation and releases it upon
environmental stress. It is assumed that certain traits that arise under conditions of stress
could be useful, and would be selected for if the selective pressure remained (Reviewed
in Rutherford, 2000).
Hsp90 has also been suggested to have a major effect on morphological variation via an
epigenetic mechanism (Sollars et al. 2003). A screen for genetic factors affecting a
Drosophila ectopic outgrowth mutant identified both chromatin remodelling genes, and
Hsp83, as modifiers of the trait. Sollars et al. went on to demonstrate that the effect of
Hsp83 mutations on the trait was epigenetic. Selection for enhanced outgrowth occurred
over a short period in an isogenic strain, indicating that genetic variation did not
contribute to the phenotype. It was suggested that the effect of Hsp90 on imprinting
could be a general mechanism by which inheritance of traits can be affected, and
contribute to the effect of Hsp90 on the evolution of new traits under conditions of
environmental stress. It appears that Hsp90 can affect developmental outcomes by both
genetic and epigenetic mechanisms, although the proportion of morphological variation
caused by either mechanism is as yet unknown (Sangster et al. 2003).
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Figure 1.2: Model showing Hsp90 buffering of cryptic mutations. For
any developmental pathway there are multiple inputs from different WT and
mutant signalling proteins, some of which are stabilised by Hsp90. If Hsp90
function is compromised, a developmental pathway that is dependent on
Hsp90 stabilisation of many proteins or that contains other mutations may be
affected, and the developmental outcome altered (Rutherford and Lindquist,
1998).
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1.3 Heat shock proteins and the stress response
A short period of heat stress during mammalian embryonic development has been shown
to protect against a further, more severe heat shock. This protection is concurrent with a
reduction in general protein synthesis, and the upregulation of a specific group of
proteins. These are defined as Heat Shock Proteins (HSPs) simply by the fact that they
are upregulated in response to a temperature elevation, but are also activated by many
other factors such as hypoxia, ethanol and glucose deprivation (Walsh et al. 1997). HSPs
have been identified in all organisms studied. The primary function of many HSPs is to
assist in the folding of newly translated or damaged proteins, so that they are often
described as "chaperone" proteins. A large body of work has been carried out to
investigate almost all aspects of HSP structure, function and regulation (Reviewed in
Latchman 1999).
Many of the heat shock proteins have a constitutive form that is dynamically expressed
during embryogenesis, suggesting important functions in specific stages of development
(Tanguay et al. 1993, Vamvakopoulos, 1993, Walsh et al. 1997, D'Souza and Brown
1998). Expression of the inducible form is usually relatively restricted under normal
conditions, but more ubiquitous during heat shock (Krone et al. 1997).
Complex mechanisms exist to ensure a rapid induction of HSP expression, and a
downregulation of the translation of all other proteins, in response to stress (Reviewed in
Sierra and Zapata, 1994, Reviewed in Morimoto, 1998). HSPs are transcriptionally
regulated by heat shock transcription factors (HSFs), which bind heat shock elements
(HSEs) in the 5' UTR (untranslated region) or promoter region. HSF1 is the most
important of these. Under normal conditions, HSF1 is kept in a monomeric, inactive
form by dynamic association with a complex containing Hsp90 and Hsp70 (Guo et al.
2001). Upon heat shock, HSF1 forms active trimers and binds HSEs in HSP genes, to
activate transcription. When the levels of HSPs increase, an HSF1-Hsp70-Hsp40
complex forms which dissociates from the DNA, and HSF1 eventually forms monomers
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again, in association with Hsp70 and Hsp90 (Morimoto 1998, Guo et al. 2001, Figure
1.3).
Induction of HSP results in thermotolerance that protects sensitive developmental
processes from the damaging effects of heat stress, mainly apoptosis due to the build-up
of unfolded proteins. Apoptosis in the developing embryo causes malformations, and is
the cause of the CNS defects commonly observed after severe heat stress. HSP induction
in thermotolerant embryos helps to prevent protein damage, but this survival occurs at a
cost, however, as downregulation of normal protein expression causes a developmental
delay (Walsh et al. 1999).
1.4 HspdO structure and function
Hsp90 is unique among the chaperone proteins, in that under normal conditions it
interacts with specific kinases and transcription factors important in development, such
as the steroid hormone receptors, Raf kinase, v-src, and p53 (Reviewed in Richter and
Buchner, 2001, Reviewed in Picard, 2003, Figure 1.4). It is this specificity for a subset
of cellular proteins that makes the role of Hsp90 in buffering the effects of mutations so
important during development. When Hsp90 function is compromised
pharmacologically, or by mutation, the output of developmental signalling pathways is
affected (Picard et al. 1990). This is analogous to the situation that would occur if Hsp90
was sequestered by unfolded proteins due to environmental stress. Many of the Hsp90
client proteins are important in human disease, as well as ageing and the immune
response (Csermely et al. 1998, Ishii et al. 1999, Smith et al. 1998, Harvey et al. 2002,
Soti and Csermely 2002). This has led to a great deal of interest in Hsp90, and its
structure, biochemical function and interactions have been intensively studied.
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Figure 1.3: Model of Hsp90 transcriptional regulation. In normal
conditions HSF1 is in an inactive form, bound in a complex including Hsp70
(1). Under stress, HSF1 forms a trimer, enters the nucleus (2), binds the
HSE (3), and is phosphorylated (4). The HSP is transcribed until it
accumulates and binds to the HSFs to inhibit transcription (5). The HSF1-
Hsp70 complex dissociates and leaves the nucleus (6), and HSF1 returns to








Figure 1.4: The dual function of Hsp90, as a chaperone of a specific set
of proteins during normal conditions, and a general chaperone of
unfolded proteins during stress (Reproduced from Mayer and Bukau,
1999).
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1.4.1 The Hsp90 family
In humans there are two Hsp90 genes, HSP90a and /3 (to be referred to as Hsp90a and
b). Orthologues for these have been identified in other vertebrates, the most studied
examples of these being the mouse, chicken and zebrafish. There are also two Hsp90
genes in yeast, but surprisingly only one form of Hsp90 (Hsp83) has been identified in
Drosophila. In Arabidopsis there are 7 Hsp90 family members (Krishna and Gloor
2001). The Hsp90 protein is highly conserved, with a minimum of 40% amino acid
identity between different organisms (Gupta, 1995, Table 1.1). GRP94 (Glucose
Regulated Protein 94) is the endoplasmic reticulum (ER) homologue of Hsp90
(Reviewed in Argon and Simen 1999), while TRAP1 (Tumour necrosis factor receptor
associated protein 1 )IHsp75 is present in the mitochondria (Felts et al. 2000, Pflanz and
Hoch, 2000). Hsp89aAN, or Hsp90N is thought to be an alternatively spliced form of
Hsp90a, but its function is unknown (Schweinfest et al. 1998, Grammatikakis et al.
2002).
Human Mouse Zebrafish Drosophila Yeast E.coli
Hspca/HSP90a Hsp84-3/Hsp86 hsp90a/hsp90cc Hsp83 HSP82 HtpG




Table 1.1: The Hsp90 gene family. Official MGD mammalian nomenclature in bold
(http://www.informatics.jax.org/, Blake et al. 2003).
The alpha and beta forms share a high level of sequence identity, but seem to have
slightly different functions. Each form is more closely related to its corresponding form
in other organisms than to its partner in the same animal. The exceptions to this rule are
zebrafish and salmon, where both forms are similar to the beta form of other organisms
(Gupta 1995, Pepin et al. 2001, Figure 1.5). The Hsp90a and b genes are very similar,





























































Figure 1.5: Phylogenetic trees showing the relatedness of the Hsp90alpha
and beta forms, (a) Nucleotide; (b) Amino acid (Reproduced from Pepin et at.
2000).
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(Csermely et al. 1998). The Hsp90a and b proteins are difficult to distinguish at the
protein level, and are often studied jointly, as Hsp90 (Voss et al. 2000, Moore et al.
1989), although gene specific probes and antibodies to the two forms have been
developed (Nemoto and Sato, 1998, Sass and Krone 1997).
1.4.2 Hsp90 protein structure
Nearly all members of the Hsp90 protein family have two highly conserved functional
domains, connected by a flexible charged linker (Reviewed in Pearl and Prodromou
2000, Reviewed in Young et al. 2001, Figure 1.6). The N-terminal domain binds the
target protein, and has an ATP binding site (Prodromou et al. 1997, Obermann et al.
1998, Panaretou et al. 1998, Young and Hartl, 2000). The Hsp90 family is part of the
novel GHKL (Gyrase, Hsp90, Histidine Kinase, MutL) ATPase/kinase superfamily,
which also includes the Prokaryotic His-Asp signal transduction histidine kinases, the
gyrase DNA toposiomerases and the MutL-like DNA mismatch repair proteins. The
ATP binding domain of these proteins is unique, in that it contains the Bergerat
ATP-binding fold, the significance of which is unclear. This domain is targeted by
several drugs that specifically bind Hsp90 in eukaryotes, and which have proved
extremely useful in studying the structure and functions of Hsp90 in vitro and in vivo
(Reviewed in Smith et al. 1998, Reviewed in Neckers et al. 1999). The most widely
used of these are geldanamycin and radicicol (Whitesell et al. 1994, Schulte et al. 1997,
Schulte et al. 1998, Sharma et al. 1998, Schulte et al. 1999).
The C-terminal domain of Hsp90 is responsible for dimerisation (Csermely et al. 1998),
as well as participating in the chaperone function of protein folding (Minami et al. 2001,
Shaknovitch et al. 1992, Scheibel et al. 1999, Johnson et al. 2000, Nemoto et al. 2001).
The C-terminal also contains an ATP binding site that is exposed when the N-terminal
site is occupied (Marcu et al. 2000, Gamier et al. 2002, Soti et al. 2002b). The charged
linker is only present in eukaryotic cells, and may not be essential, as it varies in length
and amino acid sequence between species (Pearl and Prodromou, 2000).
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Figure 1.6: Structure of human Hsp90 family proteins. Hsp90aAN-
unique region, green; GRP94-unique regions, purple (Schweinfest et al.
1998, Argon and Simen, 1999, Felts et al. 2000).
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1.4.3 Hsp90 protein function
The a and b forms of Hsp90 are very similar in sequence, but differ markedly in their
regulation. Hsp90b is constitutively expressed (Voss et al. 2000) and is only weakly
inducible, while Hsp90a is expressed at lower levels under normal conditions but is a
great deal more heat inducible (Reviewed in Loones et al. 1997). Their expression
patterns during development are very different. For example in the mouse they are both
ubiquitously expressed at a high level during early embryogenesis, with the a form
(Hsp86) at a slightly lower level, and appearing slightly later than b (Hsp84) (Barnier et
al. 1987, Moore et al. 1989, Gruppi et al. 1991, Lee, 1990, Walsh et al. 1997,
Bancewicz, 2000, Figure 1.7). The expression of Hsp86 in the adult is highest in the
testis, with moderate levels in some other tissues, while Hsp84 is ubiquitously
expressed, with the highest levels in the brain (Tanguay et al. 1993). Both forms are also
expressed in the eyes at El 1.5 to E14.5, with decreasing expression from E15.5 to
E18.5, although Hsp86 expression remains high in the retina (Tanaka et al. 1995).
Hsp90 protein is present largely in the cytoplasm of HeLa cells, and is one of the most
abundant proteins in tissues in which it is present (over 1% total protein in most
expressing mouse and human tissues, Lai et al. 1984). Nuclear expression has been
reported in rat hepatocytes (Schlatter et al. 2002). Hsp90a fused to GFP was shown to
reproduce this pattern in Swiss 3T3 (mouse embryonic fibroblast) cells under normal
conditions, with expression mainly in the cytoplasm, and a higher level of expression in
the nucleus after heat shock (Langer et al. 2003).
Hsp90 binds "abnormal" proteins. It recognises the structure of folding intermediates
(Jakob et al. 1995), and can act either as a molecular chaperone, assisting in the
refolding and reactivation of denatured proteins, or it can initiate degradation. The
interaction that occurs with the target protein is dynamic, with a constant association and
dissociation that prevents reactions with the wrong substrates, and allows proper folding
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Figure 1.7: Expression of Hsp90 homologues in the mouse at
embryonic day 10.5. (a) Hsp86 (Hsp90a); (b) Hsp84 (Hsp90b).
(Reproduced from Bancewicz, 2000).
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to occur. Other chaperones are usually required for the final folding of substrates
(Reviewed in Parsed and Lindquist, 1993, Mayer and Bukau, 1999, Caplan, 1999). The
interaction of Hsp90 with its substrate is thought to occur usually as a cycle controlled
by the binding and release of ATP by the Hsp90 dimer (Reviewed in Young et al. 2001).
ATP is bound by the Hsp90 dimer, containing a substrate protein. This changes the
conformation of the dimer to a closed ''molecular clamp" around the substrate,
reminiscent of MutL and DNA gyrase. ATP hydrolysis accompanies the release of the
substrate. (Grenert et al. 1997, Prodromou et al. 1991, Obermann et al. 1998, Panaretou
et al. 1998, Prodromou et al. 2000, Weikl et al. 2000, Young and Hartl, 2000, Richter et
al. 2001, Meyer et al. 2003, Figure 1.8). Although both forms of Hsp90 are sometimes
coexpressed, evidence for the existence of heterodimers remains controversial (Perdew
et al. 1993, Gamier et al. 2001).
Hsp90 functions as part of several different multimolecular complexes with many
cochaperones. These include Hsp70, p23, and proteins containing the tetratricopeptide
repeat (TPR), such as the immunophilins, and p48 and p6Q (Hip and Hop) (Reviewed in
Neckers et al. 1999b). It has been suggested that it is this wide variety of partner
proteins that allows Hsp90 to be involved in specific interactions in such a diverse range
of cellular processes (Grenert et al. 1997).
Most of the proteins that the constitutively expressed Hsp90 interacts with under normal
conditions are involved in signal transduction in major cell cycle and developmental
regulatory pathways. These are typically large and complex metastable proteins, with
regulatory steps involving conformational change (Reviewed in Young et al. 2001).
They include kinases such as pp60v src, the src related tyrosine kinases and Bcr-Abl, and
also transcription factors, including p53, and the steroid receptors. Other unrelated
clients are actin, tubulin, calmodulin, the cystic fibrosis transmembrane receptor,
telomerase, and the SV40 large T-antigen (Reviewed in Picard, 2003). Hsp90 is
involved in many different stages of their maturation, but does not affect the stability of
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Figure 1.8: The conformational switch of Hsp90. Binding of ATP changes
the conformation of Hsp90 to the closed molecular clamp form (Reproduced
from Pearl and Prodromou, 2000).
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levels of the proteins it interacts with decrease over time and then gradually increase
again after inhibition is removed, as only the newly synthesised proteins are affected
(Schulte et al. 1997, Sakagami et al. 1999, Marcu et al. 2000b). The most
comprehensively studied of the Hsp90 clients are the steroid hormone receptors (SHRs).
A model has been proposed in which Hsp90 keeps them in an activatable monomelic
state in the cytoplasm. When they contact the hormone they dissociate from Hsp90,
dimerise, enter the nucleus, and activate transcription (Nathan and Lindquist, 1995,
Ylikomi et al. 1998, Reviwed in Buchner, 1999, Reviwed in Mayer and Bukau, 1999).
Hsp90 is essential for development in eukaryotes. Heterozygous Hsp84 (Hsp90b)
knockouts in mice are phenotypically normal, while homozygotes have placental
abnormalities and die at E10.0-10.5 (Voss et al. 2000). Only 45% of embryos cultured in
the presence of Hsp90-specific antibodies survive to day 7 of development (Neuer et al.
1998). A knockout of both Saccharomyces cerevisiae genes prevents growth under any
conditions (Borkovitch et al. 1989). In Drosophila, homozygous Hsp83 mutations are
lethal (Rutherford and Lindquist, 1998). The Hsp90 homologue in E.coli (HtpG),
however, is not essential, and the only effect seen on homologous mutants is a small
reduction in growth at increased temperatures (Bardwell and Craig, 1987). The
importance of Hsp90 in individual developmental processes has also been demonstrated.
It has been shown to be involved somitogenesis (Krone and Sass, 1994, Sass et al. 1996,
Sass and Krone, 1997, Sass et al. 1999), spermatogenesis (Lee, 1990, Gruppi et al. 1991,
Yue et al. 1999), in development of the CNS and brain (Walsh et al. 1997, D'Souza and
Brown, 1998, Calabrese et al. 2002), the placenta (Voss et al. 2000), and the eye
(Tanaka et al. 1995, Kojima et al. 1996).
Although a null mutation in Hsp90b is lethal in homozygous mice, heterozygotes show
no obvious phenotype (Voss et al. 2000). Point mutations however, can cause a
phenotype in S. cerevisiae, and have been useful for in-vivo studies of Hsp90 protein
function (Nathan and Lindquist 1995). In humans several polymorphisms have been
identified, including one heterozygous viable missense mutation that appears to have no
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deleterious effect (Passarino et al. 2003). A missense mutation has also been identified
among infertile men, and may be associated with azoospermia (Yamamoto et al. 2002).
Point mutations have been identified in Drosophila that were lethal in homozygotes but
viable in transheterozygotes, causing only fertility defects (Yue et al. 1999). Also in
Drosophila, point mutations have been discovered in two separate studies, which affect
the severity of mutant eye phenotypes in heterozygotes (Cutforth and Rubin, 1994, van
der Straten et al. 1997). The effect of Hsp82 mutations on Drosophila eye phenotypes is
evidence that Hsp90 may be important for eye development in other organisms, and that
a reduction in Hsp90 function may also affect mutant eye phenotypes.
1.5 Zebrafish as a model system to study Hsp90 buffering of
developmental defects
The Hsp90 protein is highly conserved, from Drosophila to higher organisms. It would
be reasonable to expect, therefore, that most of its functions are also conserved. Study of
non-Mendelian diseases like MAC, and mouse mutants with variable phenotypes such as
Pax6 (Hill et al. 1991) or Foxcl (Forkhead box CI)/Mfl (Kume et al. 1998), show that
hidden genetic variation also exists in vertebrates. This variation may also be subject to
the same Hsp90 buffering seen in Drosophila. Although the buffering mechanism is
interesting from an evolutionary point of view, it might also be important for
understanding hereditary disease in humans.
1.5.1 Zebrafish as a model organism
Rare developmental disorders are difficult to study in the human population, especially
when several factors are involved, and there is a wide variation in phenotype. Model
organisms are therefore extremely valuable, as they enable the study of specific genetic
and environmental factors in a controlled population. The zebrafish, Danio rerio is
increasingly used as a model organism for developmental and genetic studies. It is
particularly suited to this type of work for several reasons. The life cycle is 2-3 months,
and adults can lay approximately 200-300 eggs once a week. The chorion is transparent,
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and development can be viewed in detail by light microscopy. The larvae hatch at 2-3
days post fertilisation (dpf), and can feed independently at 5-6 days (Nusslein-Volhard et
al. 2002). This allows large scale experiments to be carried out on a regular basis.
Additional benefits are low maintenance costs, and the ease of microinjection into the
zygote. The fundamental developmental mechanisms of the zebrafish are very similar to
other model organisms, so that it can be used to study vertebrate developmental
processes, and disease mechanisms (Reviewed in Dooley and Zon, 2000, Kimmel,
1989).
These properties of the zebrafish make it suitable for large scale genetic screens.
Hundreds of mutants have been produced by ENU mutagenesis, and are available at low
cost from several stockcentres (Haffter et al. 1996, Driever et al. 1996). These mutants
are mostly recessive, and phenotypically characterised, but not mapped. Genetic maps
are available, with an increasing number of markers, and the zebrafish genome is
currently being sequenced as part of an international effort, so that the mapping and
identification of genes should become increasingly easier (Kelly et al. 2000,
Postlethwait et al. 1998). New strategies are being developed to make genetic analysis in
zebrafish easier. Insertional mutagenesis allows new mutations to be mapped (Golling et
al. 2002, Talbot and Hopkins, 2000), while coupled mutagenesis and mapping
(sometimes referred to as "tilling") increases the efficiency of chemical mutagenesis
screens (Wienholds et al. 2002, Rawls et al. 2003). Other powerful approaches for the
analysis of gene function are the use of pharmacological agents that reproduce certain
phenotypes, overexpression studies, and knockdown of gene expression with antisense
oligonucleotides (Patton and Zon 2001). Targeted gene knockout has not been achieved
in zebrafish, due to difficulties in culturing ES cells. Germ line chimeras, however, have
been produced, so that it is reasonable to expect that homologous recombination may be
possible in the near future (Ma et al. 2001).
One difference between zebrafish and mammalian genetics is the relatively recent
genome duplication that appears to have occurred in the zebrafish lineage (Taylor et al.
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2003). It has been proposed that duplicated genes can be preserved by alterations in their
regulatory elements that confer different roles on very similar genes (Force et al. 1999).
Zebrafish appear to have retained duplicates of many genes. This allows the dissection
of the roles of genes that are essential for survival in higher organisms, as viable
mutations are more likely to occur.
Fish have already been used to study the effects of toxins in the environment, and work
has been carried out to investigate the possibility of using HSPs as an indicator of toxic
damage (Bierkens, 2000, Reviewed in Langheinrich, 2003). Notably, a GFP reporter
driven by the Hsp70 promoter has been used to detect toxic levels of cadmium in
zebrafish embryos (Blechinger et al. 2002). Zebrafish are particularly suited to a study
of environmental effects on development because all the variables of their environment
can be controlled very easily, large numbers of embryos can be treated, and any defects
can be easily observed at any time of development. The increasing characterisation of a
large number of mutants also provides an excellent resource for studying different
developmental pathways, and the possible involvement of Hsp90 buffering.
1.5.2 Zebrafish eye development
The zebrafish is an excellent model for the study of eye development, as the eye
develops rapidly and is functional at just 2 dpf (Appendix A). The development and
morphology of the eye is essentially conserved from zebrafish to humans (Easter and
Malicki 2002). Development begins with the evagination of the optic vesicles from the
future diencephalon. Contact between the optic vesicle and the overlying surface
ectoderm stimulates formation of the lens placode, which invaginates to form the lens
vesicle. The optic vesicle invaginates to form the optic cup, with the optic fissure that
closes around the hyaloid artery and vein. The lens buds off from the ectoderm, while
the optic cup differentiates into the different layers of the neural and pigmented retina

































Figure 1.9: Vertebrate eye development, (a) Formation of the retina and
lens vesicle (Reproduced from Gilbert 2000); (b) Formation and closure of
the optic fissure (Reproduced from O'Rahilly and Miller, 1987).
Several screens have been carried out in zebrafish to identify mutations that cause
morphological defects in the eye, as well as behavioural defects indicative of a loss or
reduction of vision (Fadool et al. 1997, Neuhauss et al. 1999, Doerre and Malicki, 2002,
Vihtelic and Hyde, 2002, http://www.eb.tuebingen.mpg.de/eye-screen/screen.html).
These studies have contributed to the detailed analysis of eye development and
neurogenesis, as well as providing models of human eye disease (Reviewed in
Goldsmith, 2001).
1.5.3 Hsp90 in zebrafish development
In zebrafish, the expression of different HSPs, and the effects of heat shock on
development have been well characterised (Reviewed in Krone et al. 1997b, Roy et al.
1999). The hsp90a and b genes (referred to as Hsp90 a and b) have been mapped and
cloned in zebrafish (Krone and Sass, 1994), and their expression patterns are known
(Table 1.2). Hsp90b is highly expressed at normal temperatures, mainly in the CNS.
During heat shock it is expressed at only slightly increased levels, and then still mainly
in the CNS (Sass et al. 1999, Krone et al. 1991, Sass et al. 1996, Reviewed in Krone et
al. 1997b, Figure 1.10). Hsp90a is expressed at relatively low levels at normal
temperatures, in select muscle progenitor cell groups during short periods of fast and
slow muscle development. During heat shock, it is expressed at very high levels in all
tissues. In the chick and mouse Hsp90 is also expressed in somitogenesis, but is present
in other tissues. It may be that as both genes in zebrafish appear to have arisen from
duplication of the Hsp90b form, both forms fulfil the same role as seen in other
organisms, but the division of Hsp90 function between them is different.
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Figure 1.10: Hsp90 expression in zebrafish embryos at normal
temperatures, (a) Hsp90a, 16h; (b) Hsp90b, 16h; (c) Hsp90a, 17h;
(d) Hsp90b, 20h. a, anterior. (Reproduced from Sass et at. 1996, Lele et al.
1999).
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Protein Control (28.5°C) 37°C, 1 hour 4% ethanol Known tissue-specificity
Hsp90a +/- ++++ + Putative myogenic cells
Hsp90b ++ +++ ++ CNS, possible other tissues
Hsp70 - ++++ + Not determined
Hsp47 +/- ++++ +++ Type II collagen expressing cells
Table 1.2: Relative levels and tissue-specificity of zebrafish heat shock protein mRNAs
(Reproduced from Krone et al. 1997b).
The effect of the Hsp90 inhibitor geldanamycin during early development has been
characterised in zebrafish by Lele et al. (1999). Geldanamycin inhibits Hsp90 in the
same specific manner as in other organisms. The predominant, and lethal effect of
treatment before gastrulation, is that some, but not all of the muscle cell groups that
express Hsp90a are affected. Other phenotypes are also observed, including reduced
pigmentation, small eyes, disrupted development of the fore- and midbrain, and defects
of the circulatory system. These are all effects on the tissues that express Hsp90, and
therefore may be due to specific inhibition of Hsp90. The fact that certain structures
develop normally shows that Hsp90 is only required for the differentiation of specific
tissues at specific time points. Inhibition must therefore be carefully timed to disrupt
their development.
1.6 Aims and objectives
This study was conducted to question whether Hsp90 is a buffer of developmental
defects such as MAC in vertebrates, using zebrafish as a model system. This hypothesis
is based on the model outlined in Chapter 1.2 (p24): that Hsp90 can buffer the effects of
mutations either directly, or indirectly via effects on proteins in developmental pathways
(Figure 1.2). It was hypothesised that Hsp90 buffering could be identified by
compromising Hsp90 function during development in mutant strains, and assessing
whether the penetrance or severity of the phenotype was affected. The first aim was to
assess the effects of several Hsp90 inhibitors on zebrafish embryos, and to identify the
critical time during which developmental defects can be induced. A treatment level
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would then be identified for each inhibitor that caused only very mild effects, which
might reveal the phenotype of mutations buffered by Hsp90. This dosage and timing
would then be used to treat several eye mutants: sunrise, dreumes and microps. WT
embryos were also to be treated, to identify whether any hidden or cryptic variation
existed in these strains.
If Hsp90 does buffer variation in mutant zebrafish lines, this mechanism is likely to be
conserved in mammals. The mutations that are affected could be mapped, and studied in
zebrafish, to identify the Hsp90 clients important in the buffering mechanism. This
knowledge could then be applied to the study and treatment of human diseases.
There are two copies of Hsp90 in vertebrates, including zebrafish, so it may not be
practical to attempt to study buffering using mutants, as was done in flies. Using the
pharmacological inhibitors, however, allows both forms of Hsp90 to be inhibited at the
same time. As vertebrate development is far more complex than that of Drosophila or
Arabidopsis, it was expected that a far higher level of inhibition might be required to
compromise Hsp90 buffering. Also the two copies of Hsp90 present in zebrafish could
provide an extra layer of buffering, or alter the way in which development is affected by
Hsp90 inhibition. This is one reason why it may prove easier to use mutants with a
known phenotype, and almost Mendelian inheritance, to look at alterations in inheritance






2.1 Zebrafish stocks and animal husbandry
The zebrafish mutants sunrise, dreumes and microps were created as part of an ENU
mutagenesis screen (Haffter et al. 1996), and were obtained from the Tubingen zebrafish
stockcentre. The WT lines golden (gol) and WIK were provided by the Currie
Laboratory.
Zebrafish were raised, maintained and bred according to methods outlined in the
Zebrafish Book (Westerfield, 1995), and with assistance from HGU technical staff and
members of the Currie laboratory. Embryos were staged according to Kimmel et al.
(1995) (Appendix A).
2.2 Hsp90 inhibitors
Novobiocin (Sigma) was dissolved in water to make a 50 mg/ml stock. A 25 mM stock
of radicicol (Sigma) was made in 100% EtOH. Both these stocks were stored at -20°C.
Geldanamycin (Sigma, AG scientific, donated by Peter Csermely, Semelweis
University, Hungary, and donated by the Drug Synthesis and Chemistry Branch,
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis,
National Cancer Institute, USA), and geldampicin (also donated by the NCI) were
dissolved in 100% DMSO, to make a 5 mg/ml stock, and stored at -70°C. For treatment
of zebrafish embryos, serial dilutions were made using the appropriate solvent, before
adding to system water.
Geldanamycin precipitated out when added at a certain concentration to water, with
yellow crystals forming on the bottom of the dish, as well as on the surface of the water.
The concentration at which precipitation occurred varied between suppliers.
Precipitation occurred at 10 pM for geldanamycin supplied by the NCI, and 15 pM for
AG Scientific. Yellow crystals did not form with geldanamycin from Sigma, for
concentrations up to 20 pM.
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2.3 Treatment of zebrafish embryos
2.3.1 Hsp90 inhibitors
Embryos were collected from breeding pairs or as a spawning from a tank of adults. To
weaken the chorion embryos were incubated in a 0.025 to 0.1 mg/ml solution of protease
in 30 ml of system water in a petri dish for several minutes (timings required varied
according to batch of protease), rinsed ten times, and a hole manually torn in the chorion
with watchmaker's forceps. Embryos that had reached the correct stage were transferred
to 30 ml system water containing the Hsp90 inhibitor, and incubated at 28°C (normal
temperature). Controls contained same volume of carrier solvent as experimental plates.
After 18 h embryos were rinsed five times in system water containing methylene blue.
Larvae were examined between 24 and 144 hpf using a dissection microscope, and the
criteria outlined in Haffter et al. (1996). To anaesthetise larvae a 1/30 solution of tricaine
stock was used.
Protease: Type 1, Sigma, 5 mg/ml stock in dtLO, store at -20°C in 1 ml aliquots.
Tricaine: Ethyl-3-aminobenzoate methanesulfonate salt, Sigma; 4% in dfLO, adjusted to
pH7 with Tris pH9, freeze or store working stock a 4°C.
At 1 dpf (24-32 hpf) embryos were scored as dead if necrotic and discoloured.
Methylene blue is used as a sterilising agent in water containing embryos before 5 dpf
(approximately 2 ml of 0.1% methylene blue in 1 litre of system water), as it inhibits the
growth of mould (Westerfield, 1995). It was established during initial novobiocin
experiments, that system water without methylene blue must be used, as a blue
precipitate forms on addition of novobiocin.
Larvae were humanely killed at 5 dpf by immersion in a more concentrated solution of
tricaine, and fixed for staining or sectioning as required.
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2.3.2 Heat shock
Heat treatment was carried out in sealed petri dishes containing 30 ml system water and
floating on a water bath for 30-60 min at 30-40°C, followed by a return to 28°C.
2.4 Quantitation and statistical analysis of severity of eye phenotypes
Quantitative scoring of the sri phenotype was carried out by taking digital photographs
of each eye at the same magnification for all embryos. Segment analysis was then used
to measure the area, major axis, eccentricity (irregularity) and standard deviation of the
radius (SD radius, a measure of ellipticity) of the pupil and the outer edge of the retina.
This was done by using IPLab software to draw a line around the pupil and outer edge of
the retina, and calculate different parameters (Figure 4.2b, pl05). Eccentricity is
V[(major axis)2-(minor axis)2]/(major axis) for the region of interest, where a value of
zero is given for a circle, and 1 for an extreme ellipse. A t-test was used to calculate the
significance of the difference between the means ((t = mean (difference)/"^ variance
(difference), see Appendix B for an example of the working).
Scoring of the sri phenotype was carried out blind wherever possible, sri embryos from
each treatment group were anaesthetized and sorted into 6 well tissue culture dishes
according to the criteria A B and C, outlined in Chapter 4 (Table 4.4, pl06). Statistical
analysis was carried out as described in Chapter 4 (pl04), using the t-test descibed
above, and was designed by Andrew Carothers (HGU statistician).
2.5 Microscopy and image analysis
Larvae were anaesthetised and immobilised in 4% methylcellulose (Sigma), in a
depression slide, where appropriate.
Zebrafish larvae were photographed using a Leica Fluo III stereomicroscope fitted with
an RS Photometries Coolsnap digital camera, and IPLab software (version 3.2 and 3.6).
Segment analysis was carried out using the IPLab software.
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Sections were photographed (brightfield) using a Zeiss Axioplan 2 fitted with an RS
Photometries Coolsnap HQ digital camera and IPLab software. A Netz Power ebq 100
UV light source and filter "GFP2" were used to detect GFP expression.
For immunofluorescence, photographs were taken with a Zeiss Axioskop fitted with a
Princeton Instruments digital camera, and a Netz power UV light source.
2.6 Microinjection of zebrafish embryos
Morpholino oligonucleotides were obtained from Gene-Tools, LLC (USA) as
lyophilised pellets. Each 300 ng pellet was dissolved in 60 pi dHaO to make a 5 mM
stock, and stored at -20°C. 9 pi of each dilution from this stock was added to 1 pi of 1%
phenol red (Sigma, sodium salt) in dHaO for injection. Microinjection needles were
made from 1 mm boro-silicate capillaries (1 mm outer diameter, 0.78 mm inner
diameter, Harvard Apparatus) with a CFP micro-electrode puller. A Narishige EM 300
microinjector was used, with a dissecting microscope to inject the morpholinos into the
cytoplasm of 2-4 cell stage embryos.
For mRNA injection, 9 pi of RNA was mixed with 1 pi phenol red, and injected as for
morpholinos. GFP expression was detected from 24 hpf.
2.7 Histology
2.7.1 Wax embedding and microtome sectioning of zebrafish embryos
Fixing embryos:
1x5 min 50% EtOH
1x5 min 70% EtOH (Embryos may be kept in 70% EtOH at 4°C until needed)
1 x 20 min 90% EtOH
3 x 10 min 100% EtOH
Into glass bottles
3 x 20 min histoclear (last change in 58-60°C oven)
3 x 20 min hot wax in 50-60°C oven
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Embryos were embedded in wax in a 5 cm petri dish coated with glycerol (to prevent
sticking and cracking), and cooled quickly on iced water. 5-7 jiM microtome sections
were cut, and floated onto slides (TESPA (3-aminopropyl-triethyloxysilane) coated or
Superfrost Plus electrostatically charged slides (BDH) if slides to be used for
immunohistochemistry) in a 45°C water bath. Slides were dried in a 50°C oven
overnight, and stored at RT.
Dewaxing: 2x5 min xylene
2 x 5 min 100% EtOH
1 x 5 min 90% EtOH
1 x 5 min 70% EtOH
1x5 min 50% EtOH
1 x 5 min 30% EtOH
1x5 min dH20
De-waxed sections were stained with methylene blue and mounted with DePex
mounting medium (Gurr, BDH).
2.7.2 Antigen retrieval
Nuclear antigens are often affected by the processing of wax sections. For effective
staining with p48, an antigen retrieval step was used.
Make stocks of tri-Sodium citrate (0.1M) and Citric acid (0.1M) (pH 6.0):
41 ml tri-sodium citrate
9 ml citric acid
450 ml dH20
Boil buffer in microwave. Put slides in hot buffer and microwave on full power for
30 sec, rest 1 min, then full power again for 30 sec. Allow slides to cool in buffer for
20 min at RT. Wash slides briefly in PBS.
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2.7.3 Immunofluorescence
De-waxed sections were circled with a PAP pen, and washed with PBS, before
incubation in blocking agent (PBS with 1% BSA and 2% normal serum) for at least 2 h
at RT. Sections were then incubated overnight with primary antibody (Table 2.1, p58) in
blocking agent at 4°C, followed by 2 hours of 20 min PBS washes. Sections were
incubated with a fluorescently labelled secondary antibody (Table 2.2, p58) in blocking
agent for 2 h at RT, followed by 2 hours of 20 min PBS washes. Slides were mounted
with Vectashield mounting medium (Vector). Slides can be store at 4°C for several
weeks. Double staining was carried out by incubating slides with both primary
antibodies simultaneously, followed by both secondary antibodies.
TESPA coated slides
Dip 5 racks of 20 glass microscope slides for 20 sec in each of:
Step 1
10% HC1 in 70% EtOH
dH20
100% acetone Air dry/ 5 min in oven
Step 2
2% TESPA (3-aminopropyltriehoxysilane, Sigma) in acetone
100% acetone
100% acetone Air dry/ 5 min in oven
Store at RT for up to 4 weeks. After this, step 2 must be repeated.
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2.8 Western Blotting
2.8.1 Preparation of lysate from zebrafish embryos
(adapted from Westerfield (1995), p9.2)
Decorionate 50-100 embryos and rinse three times in cold Ringer's.
Ringer's:
116 mM NaCl 11.6 ml 5 M
2.9 mM KC1 1.45 ml 1 M
1.8 mM CaCl 0.9 ml 1 M
5 mM HEPES 25 ml 0.1 M
adjust to pH7.2
dH20 to 500 ml
Transfer to cold Ringers with EDTA and protease inhibitors in petri dish:
50 ml Ringers
5 ml 10 mM EDTA, pH7.0
150 pi Protease inhibitor solution (approx 250 pi dEbO with 1 tablet Complete
mini ETDA free protease inhibitor tablets Roche cat no. 1 836 170)
5 ml Tricaine stock
De-yolk by pipetting through drawn-out glass pastette with a pipette gun. Rinse twice in
cold Ringer's. Spin to pellet embryos and remove liquid. (At this stage embryos can be
transferred to a cryotube, quick frozen in dry ice/ethanol and stored at -70°C). Add
200 pi SDS sample buffer, transfer to a small mortar and homogenise (x50 turns). Boil 5
min in a water bath. Centrifuge for 1-2 min at 4°C and transfer supernatant to a new tube
(re-homogenise if significant pellet). Freeze at -70°C or run immediately.
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SDS sample buffer (10ml): Alternative, 2x (minus B-Me, 5ml):
0.63 ml 1 M Tris-HCl, pH6.8 0.5 ml 1 M Tris-HCl, pH6.8 (or 6.9)
1.0 ml glycerol 1.0 ml Glycerol
0.5 ml B-mercaptoethanol 0.5 ml 2M DTT
1.75 ml 20% SDS 2.0 ml 10% SDS
6.12 ml H2O (75 pil Bromphenol Blue)
Store in aliquots at -20°C.
0.95 ml dH20
2.8.2 Quantitation of protein samples
A Bradford assay was used to assess the relative amounts of protein in each lysate, and
allow equal loading. A Protein assay kit was used (BIO-RAD Protein assay dye reagent,
or Pierce Coomassie Plus protein assay reagent). Samples were diluted at least 1/100 in
dH20 if SDS buffer was used. The standard microassay procedure was followed
according to the manufacturers instructions, and the OD 595 was measured using a UV
spectrophotometer.
2.8.3 SDS-polyacrylamide gel electrophoresis
A denaturing (SDS) polyacrylamide gel was prepared in a BIO-RAD Mini-PROTEAN 3
Cell, or a Hoefer SE 600 Vertical Slab Unit. The appropriate percentage resolving gel
was made Sambrook et al. (1989) pl8.52, poured to allow approximately 1 cm below
the comb for the stacking gel, and overlaid with 1 ml Isobutanol saturated with H20
(mix 1:1 Isobutanol and dH20) while setting. Isobutanol was then removed, and the
stacking gel was added and allowed to set.
Stacking gel: 1.48 ml dH20
0.25 ml 1 M Tris pH6.9
0.26 ml BIO-RAD 30% Acrylamide/Bis solution 20:1
10 pi 20% SDS
10 pi 10% APS (Ammonium Persulphate)
2 pi TEMED (N, N, N', N'-tetramethylethylenediamine)
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5 x SDS running buffer: 15.1 g Tris base (Tris(hydroxymethyl)methylamine)
72 g Glycine
25 ml 25% SDS
Made up to 11 with cfflhO
6x SDS loading buffer: 3.5 ml 1 M Tris-HCl pH6.8 (350 mM
3 ml glycerol
1 g SDS
0.93 g DTT (0.6 M)
1.2 mg Bromphenol Blue
10 ml
Samples were added to loading buffer and denatured by heating for 3 min at 85°C in a
PCR block, and immediately returned to ice. The size markers used were Biorad
Prestained SDS-PAGE standards (Broad range), or Biorad SDS-PAGE Molecular
weight standards (Broad range). Mini-gels were run at 80-100 mA, for 2-3 h, and large
gels were run at 50 mA, overnight, or until the dye front reached the bottom of the gel.
2.8.4 Coomassie blue staining
Samples were often loaded in duplicate to determine whether loading was equal. The gel
was stained for 30 min in coomassie blue, and de-stained overnight in 30% MeOH, 10%
acetic acid.
Coomassie blue stain: 0.25 g Coomassie brilliant blue
(filter before use) 90 ml MeOFkHiO (1:1 v/v)
10 ml glacial acetic acid
De-stain: 30% MeOEl
10% glacial acetic acid
dH2Q
2.8.5 Semi-dry transfer of proteins
Proteins were transferred to a Elybond-P (PVDF, Amersham) membrane with a Biorad
Transblot SD Semi-dry transfer cell.
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Pre-soak the membrane in MeOH, then in transfer buffer. Cut 6 sheets of Whatman
paper to the same size as the membrane and soak in transfer buffer. Layer on the lower
electrode: 3 pieces of Whatman paper, membrane, gel, and 3 pieces of Whatman paper.
Roll with a pipette to remove trapped air bubbles. Transfer at 1.2 mA/cnT or higher, at a
maximum of 25 V for 1-2 h.
Transfer buffer: 11.4 g Tris base
54.0 g Glycine
5 ml 20% SDS
800 ml MeOH
to 1 1 with dH2Q




2.8.6 Ponceau S staining
To ensure that transfer was successful, to allow the identification of unstained markers,
and to determine if loading was equal, the membrane was stained in Ponceau S solution
(Sigma Ponceau S solution) for several minutes, and de-stained in H20.
2.8.7 Immunodetection of proteins
Membranes were blocked for 30 min at RT or overnight at 4°C in 5% dried milk in
TBST on a rotary shaker, followed by three washes (15, 5, 5 min) in TBST. Membranes
were incubated in primary antibody (Table 2.1, p58) in 5% milk in a sealed bag on a
test-tube rotator for 1 h at RT followed by three washes in TBST. HRP-conjugated
secondary antibody (Table 2.1, p58) was added in the same way, followed by three more
washes in TBST.
Detection of the secondary antibody was carried out with ECL Western blotting
detection reagents (Amersham Biosciences), according to the manufacturer's





Host Cat. no. Supplier Use Cone.
Hsp70 Human Polyclonal Rabbit SPA-812 Bioquote Ltd. Western blotting 1/2000
Hsp90 Mouse Polyclonal Mouse MA3-010 Affinity
Bioreagents
Western blotting 1/500






Glucagon Porcine Monoclonal Mouse G2654 Sigma Immunofluorescence 1/500
p48 Rabbit Immunofluorescence 1/500






Table 2.1: Primary antibodies used for immunohistochemistry and western blotting.
Antigen Host Catalogue no. Supplier Detection Concentration
Rabbit Goat 170-5046 Biorad HRP conjugate 1/5000
Mouse Goat Amersham HRP conjugate 1/3000
Rabbit Goat A-11012 Molecular Probes 594, Texas red 1/200
Mouse Goat 0-6380 Molecular Probes Oregon green 1/200
Guinea pig Goat Molecular Probes 594, Texas red 1/200
Table 2.2: Secondary antibodies used for immunohistochemistry and western blotting.
2.10 Quantitative RT-PCR
RNase free reagents and lab ware were used throughout to minimise degradation of the
RNA.
2.10.1 Preparation of RNA from zebrafish embryos
Zebrafish embryos were dechorionated and transferred to a 1.5 ml centrifuge tube.
RNAlater (Ambion) could be added to this stage, stored at -70°C, and rinsed out with
dH20 when required. Embryos were homogenised (x50 turns) in 200 pi Total RNA
Isolation Reagent (ABgene), and transferred to a clean tube on ice for 5 min. 40 pi
chloroform (Sigma, 99+%) was added, and tubes were vortexed for 15 sec, followed by
5 min on ice. Samples were centrifuged for 15 min at 4°C at 13,000 rpm. The upper
phase was retained, and an equal volume of isopropanol (Sigma, 99+%) and 2 pi
glycogen (for molecular biology, Boehringer) were added, and samples left at 4°C for
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10 min or at -20°C for several hours or overnight to precipitate the RNA. Tubes were
centrifuged for 10 min at 4°C at 13,000 rpm, and the pellet washed twice with 1 ml
ice-cold 75% EtOH. Pellets were dried for 10 min at RT with lids off, then resuspended
in 50-100 pi dH20, and vortexed for 1 min. RNA was stored at -70°C.
2.10.2 RNA check gel
To check the quality of the RNA at least 2 pi was diluted in dH20 with 1 pi ethidium
bromide, and run on an agarose gel at 150V for a short time. In good quality RNA bands
representing the 60S and 40S ribosomal subunits should be clearly visible without too
much smearing.
2.10.3 DNAse treatment
10 u of RNAse-free DNAsel (1 pi Roche/Boehringer cat no. 776 785, or 10 pi Gibco
Amp. grade) was added to RNA, with lOx DNAse buffer to lx concentration, vortexed
and incubated for 30 min at 37°C. Samples were made up to 200 pi with dH20, and the
enzyme was removed by phenol-chloroform extraction, and the RNA precipitated with
2 pi glycogen, O.lx vol. 3 M NaAc, pH5.2, 2.5 x vol. 100% EtOH at -20°C for at least
one hour or overnight. Centrifuge for 10 min at 4°C at 13,000 rpm, and wash the pellet
twice with 500 pi ice-cold 70% EtOH. Pellets were dried for 10 min at RT with lids off,
then resuspended in 50-100 pi dH20, and vortexed for 1 min. RNA was stored at -70C.
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2.10.4 Reverse transcription
RT-PCR was carried out on an MJ Research PTE225 Peltier Thermal Cycler in
0.25 ml tubes.




Denature at 63°C for 5 min, and return to ice.
Add: 0.5 pi dNTPs (25 uM, ABgene)
1 pi RNase inhibitor (Roche)
2 pi glycerol
4 pi 5x first strand buffer (Gibco)
2_pL 0.1MDTT (Gibco)
19.5 pi
Heat at 45°C for 2 min. Add 1 pi superscript II RT (Gibco). Heat for a further 50 min at
45°C. Add 1 pi E.coli RNase H (Gibco), and heat 37°C for 20 min, then 5 min 80°C to
kill the enzyme.
2.10.5 Quantitative PCR
Quantitative PCR was carried out by controlling the number of reaction cycles so that
the reaction was completed in the linear portion (usually 15-20 cycles). This was done so
that differences between the relative amounts of specific cDNAs between different
treatment groups could be determined (Figure 2.1). See below for detailed PCR protocol.
Control primers for a-actin were used. An initial PCR was carried out with the control
primers at 15-20 cycles, to determine the relative amount of cDNA in each sample. The
amount of each cDNA was adjusted to give equal products for the control PCR in all
samples, and then these amounts were used for the test primers.
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Figure 2.1: Quantitative PGR. Showing progression of a PGR reaction for two samples, and the
exponential part of the curve where the difference between the two samples can be measured
quantitatively (Reproduced from Siebert, 1999).
2.11 Mutation analysis
2.11.1 Fixing of larvae for mapping
Embryos were fixed in 100% methanol (5 min then replace) and stored at -70°C.
2.11.2 Preparation of DNA from zebrafish
DNA was prepared from either whole embryos or finclips. To take a fin clip, adult
zebrafish were anaesthetised in a 1/30 solution of tricaine stock, and a razor blade was
used to remove a small piece of the tail fin. Fish were recovered in system water before
returning to tanks.
Samples in 1.5 ml centrifuge tubes were covered with 50 pi lysis buffer, and boiled for
10 min in a water bath. 10 pi proteinase K was added, and samples were incubated in a
55°C water bath for several hours, or overnight. Samples were boiled again for 10 min
in a water bath to kill the proteinase. DNA was stored at -20°C and 1 pi was used for
PCR.
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2.11.3 Polymerase chain reaction
Primer design:
The web pages http://www.cybergene.se and Primer3 (Rozen and Skaletsky, 2000) were
used to aid design of oligonucleotide primers (supplied as lyophilised pellets by MWG).
Stocks were made up to 100 pi with dH20. 100 pmol/pl working stocks were made.
Reaction mix:





0.2 mM dNTPs 0.5 pi
50 pM primers 0.5 pi
AmpliTaq 0.3 pi
dH20 to 50 pi
GeneAmp lOx buffer (Applied biosystems)
GeneAmp MgCl2 solution
of 10 mmol/pl stock (Abgene)
of each 100 pmol/pl stock
(1.5u, GeneAmp)
PCR was carried out on an MJ Research PTE225 Peltier Thermal Cycler in 0.25 ml
tubes.
PCR programme: 5 min 94.5°C denaturing
Up to 30 cycles:
30 sec 94.5°C denaturing
30 sec/Kb Tm minus 5°C annealing







To estimate the size and concentration of any DNA fragments, they were separated by
agarose gel electrophoresis. An agarose gel (High pure, BioGene or Nuseive GTG
Agarose, Biowhittaker Molecular Applications) of the appropriate percentage was made
in 1% TAE (Tris-acetate-EDTA) buffer, with 0.2 mg/ml ethidium bromide (EtBr, Sigma
or Biorad), and run in TAE buffer at 80-100 V, and the bands viewed on a UV
transilluminator. Size markers were used to allow estimation of band size, and the
relative DNA concentration. The size markers used routinely were bacteriophage lambda
DNA digested with Hindlll ('X') (Gibco BRL or Invitrogen), DNA marker X,
0.07-12.2 Kbp (Roche) and 100 bp DNA Ladder (Promega).
Fragments required for further manipulation were excised and purified using a gel
extraction kit (Qiagen), according to the manufacturer's instructions.
Distilled water was added to a final volume of 1 litre. Stock was diluted to IX with
distilled water.
2.11.5 Determining the concentration of DNA samples
A 1/100 dilution of the DNA was made, and the optical density was measured at a
wavelength of 260 nm (OD260) using a UV spectrophotometer. This was used to
calculate the concentration of DNA. An optical density of 1 is equivalent to
approximately 50 pg/ml for double stranded DNA. The ratio between the OD260 and the
OD280 gives a measure of the purity of the sample. A ratio of 1.8 indicates that the














sample is free from protein and salt impurities, while a ratio of less than 1.8 shows that
the sample is contaminated (Sambrook et al. 1989).
2.11.6 Restriction enzyme digestion
Restriction enzymes were supplied by Boehringer Mannheim or New England Biolabs.
The amount of each enzyme added was 5% or less of the reaction volume, using the
appropriate lOx buffer diluted to lx concentration with dtBO. Digests were left at 37°C
for several hours or overnight before running on an agarose gel.
A speed vac (DNA 120 Speed Vac, Thermo Savant) could be used to reduce the volume
of the digests prior to running.
If digested DNA was required for further manipulation, fragments were purified using a
PCR clean-up kit (Qiagen), according to the manufacturer's instructions.
2.11.7 Phenoi-chloroform extraction
Add an equal volume of Phenol:chloforom:isoamyl alcohol mixture (Gibco BRL),
vortex thoroughly, centrifuge for 5 min at RT. Retain the upper phase for precipitation.
2.11.8 Sequencing
PCR products for sequencing were cleaned using 1 pi Exonuclease I (Exo) and 1 pi
Shrimp Alkaline Phosphatase (SAP) per 3-10 pi DNA. Reactions were heated at 37° for
15 min, and denatured for 15 min at 80°C on an MJ Research PTE225 Peltier Thermal

















Sequencing products were precipitated with 90 (0,1 70% EtOH (diluted from 95% EtOH,
Fisher) and 1 pi Pellet Paint (Novagen) for 15 min, and centrifuged at 13,000 rpm for
20 min at RT. The supernatant was removed and the pellet washed with 70% EtOH. The
pellet was dried for 1 min at 90°C on an MJ Research PTE225 Peltier Thermal Cycler.
Sequencing products were run out using an ABI 3100 by HGU technical staff.
Sequencing traces were analysed using Sequencher or Chromas software.
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Chapter 3
The Effects of HspdO Inhibitors on Zebrafish
Development
3.1 Introduction
Before an investigation of Hsp90 buffering in zebrafish mutants could be carried out, it
was important to establish the procedure for inhibitor treatment during development.
The protocol of Lele et al. (1999), describing geldanamycin treatment of very early
zebrafish embryos, was used as a starting point to establish the dose and timing of
Hsp90 inhibitor treatment required to cause a very low level of developmental defects. It
was also necessary to identify the most appropriate Hsp90 inhibitor to use, based on
several properties: availability, solubility, stability, cost, toxic side effects in the
embryos, and danger of toxicity to the researcher. Treatment was carried out during the
temporal "window" in development during which eye development is particularly
vulnerable.
Another factor to be taken into account was the activation of a heat shock response.
Hsp90 inhibitors are known to activate the heat shock transcription factor, HSF1, which
is in complex with Hsp90. On disruption of this complex by geldanamycin, HSF1 is
released and activates the heat shock response (Zou et al. 1998, Guo et al. 2001,
Winklhofer et al. 2001). It was therefore important to establish that developmental
defects arose due to the disruption of processes that are dependant on FIsp90, and not
due to a general down-regulation of transcription, and induction of other HSPs, caused
by the initiation of a full heat shock response (Yost and Lindquist, 1986).
3.2 Hsp90 inhibitors
A summary of the properties of some Hsp90 inhibitors and their controls is shown in
Table 3.1, and Figure 3.1a. The benzoquinone ansamycin drug geldanamycin is the most
widely used of these. Initially identified as an antibiotic (DeBoer et al. 1970), it was
later shown to have anti-tumour properties, reducing the levels of the src protein that is
responsible for oncogenic transformation of cells (Uehara et al. 1986). Src exists in






Figure 3.1: (a) Molecular structure of Hsp90 inhibitors, (b) Controls. The
names of structurally related compounds are followed by identical symbols
(Reproduced from www.sigmaaldrich.com, Chiosis et at. 2001).
68
degraded (Whitesell et al. 1994). Many other Hsp90 clients are also degraded on
geldanamycin treatment of cultured cells (Schulte et al. 1997, Sakagami et al. 1999).
Geldanamycin competes with ATP for binding of the N-terminal ATPase domain of
Hsp90 (Roe et al. 1999) and GRP94 (Chavany et al. 1996). Geldanamycin also causes
the accumulation of free radicals, but for this to occur it must be used at a far higher
concentration than is necessary to inhibit cell transformation (Reviewed in Ochel et al.
2001, Dikalov et al. 2002).
Compound Solvent Toxicity (EU) Cost/mg (Sigma) Notes





Herbimycin A DMSO Teratogenic £394.10 Not very stable
Novobiocin H20 Irritant <1p Not specific
Radicicol EtOH Harmful £42.02
Table 3.1: Readily available Hsp90 inhibitors and their properties.
The antibiotic radicicol also binds the N-terminal ATPase domain of Hsp90, but with a
higher affinity than geldanamycin (Kd is 1.2 pM and 0.019 pM for geldanamycin and
radicicol respectively) (Sharma et al. 1998, Roe et al. 1999). It also binds the Hsp90
family members, TRAP-1 and GRP94 (Schulte et al. 1999). Two other unrelated
proteins, ATP citrate lyase, and branched-chain a-keto acid dehydrogenase (BCKDHK)
are also bound by radicicol, but with a far lower affinity (Ki et al. 2000, Besant et al.
2002). Also, ATP citrate lyase is bound by a different part of radicicol to Hsp90 (Ki et
al. 2000). Herbimycin A is another benzoquinone ansamycin with antitumour activity,
which also inhibits Hsp90 binding of client proteins (Uehara et al. 1986, Whitesell et al.
1994, Sakagami et al. 1999). It is extremely unstable, however, which made it seem
unsuitable for large-scale studies.
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The antibiotic novobiocin is less toxic than the benzoquinone ansamycins. It is
particularly useful in biochemical studies of Hsp90 function, as it binds both the N and
C-terminal ATPase domains (Marcu et al. 2000, Marcu et al. 2000b, Soti et al. 2002b).
Although novobiocin also inhibits topoisomerase II, it can be used as an Hsp90 inhibitor
in cell culture, to deplete Hsp90 clients such as Rafl and v-src (Marcu et al. 2000b).
Cisplatin is another anti-tumour agent that binds the C-terminal domain of Hsp90 (Itoh
et al. 1999, Soti et al. 2002), but it also acts as a DNA intercalating agent, causing
intra-strand DNA breaks (Rang et al. 1995). Cisplatin may therefore be too toxic for
developmental studies, as well as acting as a mutagen.
Geldanamycin, radicicol and novobiocin were chosen for initial testing in vivo. Several
compounds, listed in Table 3.2, were also obtained for use as controls (Figure 3.1b).
Doxorubicin and etoposide are structurally unrelated topoisomerase II inhibitors with no
Hsp90 inhibitory activity, and can be used as negative controls for novobiocin (Marcu et
al. 2000b). Geldampicin is a benzoquinone ansamycin that differs from geldanamycin
by one side chain. It has been shown to compete for Hsp90 binding to geldanamycin
beads, but with a 100-fold lower affinity than geldanamycin (Grenert et al. 1997). It has
been accepted as having negligible Hsp90 inhibitory activity, and is therefore suitable as
a negative control (Whitesell et al. 1994, Lele et al. 1999).
Compound Solvent Toxicity (EU) Cost/mg (Sigma) Related Inhibitor
Doxorubicin h2o Toxic £10.16 Novobiocin
(Adriamycin)
Etoposide (VP16) DMSO Toxic £8.78 Novobiocin
Geldampicin DMSO Unknown n/a Geldanamycin
Table 3.2: Control compounds that do not inhibit Hsp90 activity.
70
3.3 Hsp90 inhibitor treatment of zebrafish embryos
WT embryos were treated with Hsp90 inhibitors according to the protocol outlined in
Chapter 2 (p49), to assess the dosage and timing required to cause developmental
defects. Novobiocin was used initially, as it is the cheapest, and least toxic of the drugs.
Both geldanamycin and radicicol were then tested, and radicicol was chosen as the main
inhibitor for further experiments, as it is cheaper, less toxic, and does not require DMSO
as a solvent. Geldanamycin was also used, to demonstrate whether the effects seen with
radicicol were a result of Hsp90 inhibition, or toxicity due to any particular chemical
properties of the drug.
Details of the WT strains used are given in Table 3.3. For initial experiments with
novobiocin, golden (gol) mutants were used. For nearly all the subsequent experiments,
to ensure that differences in response to the drug were due to the mutation present and
not genetic background, the Tti/AB/TL strain was used. Minor differences in genetic
background still exist, however, because if zebrafish are too inbred they fail to thrive
(Brand et al. 2002). This may be because zebrafish WT strains are not so well
established, and deleterious alleles have not been removed. It is possible therefore, that
some cryptic mutations could be present.
Strain Details Origin Reference
Tubingen (Tu) WT laboratory strain Tubingen pet shop Haffter et al. 1996
AB WT laboratory strain Oregon pet shop Chakrabarti et al. 1983
Tubingen long
fin (TL)
WT laboratory strain Fish dealer Haffter et al. 1996
WIK WT mapping strain, relatively
outbred
Wild catch, India Rauch et al. 1997
Tu/ABTL Derived from non-carriers of
mic
1996 ENU screen Heisenberg et al. 1996
mic Mixed Tu/ABTL background 1996 ENU screen Heisenberg et al. 1996
sri Mixed Tu/AB/TL background 1996 ENU screen Heisenberg et al. 1996
dre Mixed Tu/AB/TL background 1996 ENU screen Heisenberg et al. 1996
golden (gol) AB background Fish dealer Chakrabarti et al. 1983
Table 3.3: Zebrafish strains used throughout this study (http://www.zfin.org, Sprague et al.
2001).
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Embryos must have a hole torn in the chorion before inhibitor treatment, as survival was
much lower when the chorion was left intact. The chorion, together with the peri vitelline
fluid surrounding the embryos may amplify the effects of inhibitors by allowing the
drug, or its toxic by-products, to accumulate inside the chorion at a much higher
concentration (Bonsignorio et al. 1996, Gellert and Heinrichsdorff, 2001).
All three of the Hsp90 inhibitors tested; radicicol, geldanamycin and novobiocin, had a
dose-responsive effect on the development and survival of zebrafish embryos, whether
treatment was initiated before (30% epiboly to germ ring) or after (60 to 70% epiboly)
gastrulation (Figure 3.2, Appendix A). This showed that the defects observed were due
to the presence of the inhibitor. The solubility of geldanamycin in water varied between
suppliers, and limited the concentration that could be used experimentally (Chapter 2.2,
p48). A comparison of the frequency of developmental defects at a concentration that
allows over 80% survival (up to 10 pM radicicol at 30-50% epiboly, or 20 pM at 60-
70%, 15 pM geldanamycin at 60-70% epiboly, and 50 pM novobiocin at 30-50%
epiboly), shows that radicicol and geldanamycin can cause virtually 100% very mild fin
defects and less than 20% more serious defects, while novobiocin causes less than 10%
serious defects and none that are mild. This indicates that the primary activity of
novobiocin results in lethality, and that it may not be suitable for developmental studies.
3.4 Developmental defects observed after treatment with Hsp90 inhibitors
The aim of these experiments was to establish both the timing and level of Hsp90
inhibitor treatment required to cause morphological abnormalities, so that a
sub-threshold dose could be used to reveal cryptic mutations.
3.4.1 Novobiocin
When WT embryos were treated with novobiocin, starting from 30% epiboly to germ
ring stage, until 24-26 hpf (hours post fertilisation) (18h incubation), developmental
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DMSO 0 10 15 20
uM Geldanamycin
Figure 3.2: Dose-responsive effect of Hsp90 inhibitors on survival at 1
dpf and development at 5 dpf, of WT zebrafish embryos, (a) Novobiocin;
(b,c) Radicicol; (d) Geldanamycin. Survival (black), mild fin defects (spots),
major developmental defects (stripes). Treatment was initiated at the 30%
epiboly to germ ring stage (a,b), or 60 to 70% epiboly (c,d). Standard error is
indicated where bars represent more than one experiment. Y axis, %
embryos.
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defects were observed at concentrations over approximately 50 uM. A variety of defects
were seen in embryos that survived beyond 24h, including heart oedema, very severe
oedema with growth retardation and reduced pigmentation, growth retardation, somite
defects, microphthalmia, anophthalmia, rachischisis (non-closure of the neural tube, or
spina bifida) and other notochord defects (Figure 3.3 and 3.4). Survival rates at these
concentrations were however very low. The characteristic shortened embryos seen by
Lele et al. with geldanamycin were not observed.
In studies of the effects of toxic chemicals on zebrafish embryos, survival and growth
were the most sensitive parameters for nearly all compounds tested (Roex et al, 2002).
Other defects that often develop on exposure to toxic compounds are reduced
circulation, reduced pigmentation, and rachischisis (Baumann and Sander, 1984, Nagel,
2002, Schulte and Nagel, 1994). All of these phenotypes are observed on exposure to
novobiocin, suggesting that they are due to toxic effects of the drug and not Hsp90
inhibition. Coumarin antibiotics such as novobiocin are known to inhibit eukaryotic
topoisomerase II (Fisher et al. 1992). Topoisomerase II activity is essential for viability
in eukaryotes, as demonstrated by studies in yeast that have shown that topoisomerase II
knockouts are lethal, due to defects in chromosome segregation (Rose et al. 1990). The
topoisomerase II inhibitor etoposide has been shown to cause cell cycle arrest in
zebrafish embryos (Ikegami et al. 1997).
Although novobiocin is less toxic than geldanamycin or radicicol on a molar basis, a
high dose of novobiocin must be used to inhibit Hsp90 in cell culture (1 mM, Marcu et
al. 2000b), and it was suggested that at this concentration the topoisomerase II inhibitory
activity may confound the effects seen on development (personal communication,
Leonard Neckers). This is confirmed by the observation that a concentration of only
0.1 mM novobiocin causes a high frequency of lethality in zebrafish embryos. Use of the
negative controls etoposide and doxorubicin might have confirmed that the primary
effect of novobiocin during development is on topisomerase II. These experiments were
not carried out however, as it had already been concluded that survival was too low for
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Figure 3.3: Developmental defects caused by novobiocin treatment.
(a) WT, 6 dpf; (b) Heart oedema, 0.025 mM, 5 dpf; (c) Very severe oedema and
growth retardation, 0.1 mM, 4 dpf; (d) Failure of the swim bladder to inflate,
0.05 mM, 4 dpf; (e) Somitogenesis defect, 0.3 mM, 3 dpf; (f) Bilateral
microphthalmia, 0.025 mM, 5 dpf.
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Figure 3.4: Notochord defects caused by novobiocin treatment.
(a) Truncated tail, 0.13 mM, 4 dpf; (b) Rachischisis, 0.02 mM, 1 dpf; (c) Bent
tail, 0.2 mM, 4 dpf; (d) Curled up on yolk sac, 0.2 mM, 4 dpf; (e) Slight
notochord irregularity, 0.075 mM, 3 dpf; (f) Bends in notochord, 0.05 mM.
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novobiocin to be used in further experiments. These experiments demonstrate the
consequences of exposure to a toxic chemical during development, and can be used as a
control in comparison with more specific inhibitors.
3,4.2 Radicicol
In WT embryos treated with radicicol from 30-50% epiboly, at a concentration of 10 pM
all the embryos were severely affected, and died between 24 and 32 hpf. These embryos
had a similar shortened body axis to those described by Lele et al. (1999) for 35 pM
geldanamycin (Figure 3.5). Geldanamycin has a far lower affinity for Hsp90 than
radicicol, and this difference may be reduced in vivo by differences in solubility and
metabolism, to give the approximately three-fold difference (on a molar basis) in activity
observed. These two lines of evidence, phenotype and concentration, indicate that the
defects observed after radicicol treatment under these conditions are due to
destabilisation of Hsp90 client proteins by specific inhibition of the Hsp90 protein. A
small volume (10-30 pi) of the known teratogen ethanol (Ahlgren et al. 2002) was used
as a solvent for radicicol, therefore a control containing the same volume of ethanol was
always carried out for each experiment.
The severe abnormalities caused by radicicol treatment close to the onset of gastrulation
may have masked any eye-specific abnormalities, so treatment was initiated closer to the
onset of eye development. The optic primordium becomes visible between 11 and
12 hpf. When radicicol is added between 7 and 8 hpf (60-70% epiboly), survival is
markedly improved. At 4-5 dpf developmental defects were scored, including heart
oedema, growth retardation, very severe oedema and growth retardation with reduced
pigmentation, failure of the swim bladder to inflate (usually inflated by 4 dpf), and
notochord defects (Figure 3.6 a-e). Part of the caudal fin was absent in a high proportion
of treated embryos (Figure 3.6f). The frequency of the developmental defects described
was dose-responsive. A concentration of 10 pM was chosen for subsequent experiments,
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Figure 3.5: WT embryos treated with radicicol have a characteristic
phenotype similar to that caused by geldanamycin. (a) 10 uM radicicol,
24 hpf, embryo almost completely necrosed; (b) Untreated, 24 hpf;
(c) 35 (iM geldanamycin, 18 hpf; (d) Untreated, 18 hpf. (c and d reproduced
from Lele et al. 1999. * and 1 indicate in-situ staining for eng-2 mRNA, that
is not relevant to this discussion).
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Figure 3.6: Developmental defects caused by radicicol treatment.
(a) Top WT, bottom growth retardation, 2.5 nM; (b) Heart oedema, 1 nM;
(c) Failure of the swim bladder to inflate, 0.1 (d) Very severe oedema
and growth retardation, 3 jiM; (e) Narrowing of the notochord, from the arrow
onwards, 14 ^M; (f) Reduced caudal fin, top WT, bottom affected, 2.5 nM.
(a-d, f) treated from 30% epiboly-germ ring, (e) treated from 60-70% epiboly.
All scored at 5 dpf.
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as mild fin defects and a low frequency of more severe defects are caused, indicating a
low level of Hsp90 inhibition (Figure 3.2).
A general developmental delay was observed after treatment with radicicol or
geldanamycin, but not geldampicin (Figure 3.7). This may be due to the destabilisation
of ubiquitously expressed Hsp90 clients that are important in growth and differentiation
of all tissues, such as p53, and the steroid hormone receptors (Reviewed in Richter and
Buchner 2001). Growth recovered after the drug was washed out, and several hours later
(approximately 3-6h) treated embryos appeared to be the same size as their untreated
sibs.
3.4.3 Geldanamycin
Geldanamycin treatment was also initiated at 60-70% epiboly. After an initial
dose-response experiment (Figure 3.2d), a concentration of 10-20 pM was used for all
the subsequent experiments. The characteristic shortened phenotype described by Lele et
al. was never observed, presumably because of the later timing and lower dose that were
used. At 5 dpf the range of developmental defects observed included some of those
caused by radicicol; growth retardation, heart oedema, very severe oedema and growth
retardation with reduced pigmentation, failure of the swim bladder to inflate, and
notochord defects. In addition to these, a possible hyperinflation of the swim bladder
(although this was very difficult to score), an irregular caudal fin in nearly all larvae
(Figure 3.8), and a cloudy appearance in the abdomen or yolk sac were observed. The
altered appearance of the abdomen may be a result of disruption of gastrointestinal tract
development or physiological function, but these defects were not scored, as they were
difficult to quantify.
The caudal fin defects observed after geldanamycin and radicicol treatment did not
occur with geldampicin, DMSO, EtOH or novobiocin. The effect on fin development,
therefore, appears to be a consequence of Hsp90 inhibition, and a demonstration that the
two structurally unrelated inhibitors are affecting the same developmental pathways.
80
Figure 3.7: Treatment of sri homozygous mutant embryos with Hsp90
inhibitors causes a developmental delay that recovers on removal of
the drug, (a) Untreated; (b) 10 radicicol. Treated from 60-70% epiboly.
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Figure 3.8: Caudal fin defect caused by geldanamcin treatment.
(a) Untreated; (b) 10 nM geldanamycin. 3 dpf embryos. Treated from 60-
70% epiboly.
82
There is no Hsp90 expression reported in the fins, but there may be factors expressed
early in development that affect the regulation or function of other proteins involved in
caudal fin development.
Differences in the defects caused by radicicol and geldanamycin may be due to
variations in metabolism or toxic side effects caused by the different chemical properties
of the compounds, as well as variations in their Hsp90 inhibitory activity. The unrelated
proteins, ATP citrate lyase and BCKDHK that are bound by radicicol may cause other
side effects when inhibited during development. It is unknown whether geldanamycin
binds any proteins outside the Hsp90 family, but for both radicicol and geldanamycin
the major substrate is Hsp90, so that other proteins are likely to play a very minor role in
their effects on development. Although radicicol and geldanamycin have been shown to
interact with most Hsp90 family members, each inhibitor may have different affinities
for these, causing different effects in certain tissues. For example, a higher level of
inhibition of GRP94 would affect tissues rich in mitochondria such as muscle and brain.
Hsp90a and b have distinct dynamic spatial and temporal expression patterns during
development (Chapter 1.4.3, p33). If these two forms were inhibited to a different extent
by radicicol or geldanamycin, it could explain some of the variation in the types of
developmental defects that are caused.
3.4,4 Eye defects
Inhibitor treatment was carried out during the window of development in which the eyes
are most vulnerable to teratogens. It was important however, to establish a level of
treatment during this period that did not have any effects on eye morphology, so that
only embryos carrying eye mutations were likely to be affected. When larvae suffered
from severe oedema, the eyes were often small and misshapen, presumably as a result of
the oedema and growth retardation already present (WT, 89/517 (17%) 10 pM,
1/282 (0.4%) EtOH, Figure 3.6d). Specific eye defects, however, were rarely observed
after geldanamycin or radicicol treatment. In one instance, smaller eyes with an irregular
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pupil occurred in one treated, and one untreated larva when Tti WT embryos were
treated with 3 pM radicicol from 30-50%. The presence of the defect in an untreated
embryo suggests that radicicol is not the primary cause. Only one eye defect, a bilateral
anophthalmia, arose among 2002 Tu WT embryos treated with 10 pM radicicol from
60-70% epiboly. A bilateral anophthalmia was also observed for one out of 48 WIK WT
embryos treated in the same way. No eye defects were ever observed in geldanamycin
treated embryos (146 WT treated at 10-20 pM from 60-70% epiboly).
The black skin pigment cells, known as melanocytes, expand in response to bright light,
and retract in darker conditions. This response is linked to visual function, so that blind
embryos have fully expanded melanocytes (Goldsmith, 2001, Dahm, 2003). This was
not observed in any of the embryos treated, suggesting that blindness did not occur.
3.4.5 Controls; Chemicals and heat shock
It was essential to use the correct controls, to be able to identify specific effects of the
inhibitors. It has already been mentioned that some defects occur with all treatment
types (heart oedema, growth retardation, very severe oedema and growth retardation
with reduced pigmentation, and failure of the swim bladder to inflate), some of which
can also occur in untreated embryos. These may be due to toxic effects of the drugs.
Geldanamycin is insoluble in water or ethanol, and was dissolved in DMSO, which is a
known teratogen (Sharma et al. 1985, Larsen and Janners, 1987). DMSO alone
occasionally caused the developmental defects common to radicicol and geldanamycin,
but at a similar frequency to the controls containing up to 30 pi EtOH, so that these
defects may be caused by other environmental effects (Table 3.4).
The similarity in frequency of developmental defects for geldanamycin and geldampicin
demonstrates the toxic effect of benzoquinone ansamycins, and suggests that for
geldanamycin, and perhaps also radicicol, the majority of the developmental defects
observed in all strains treated are likely to be caused by a toxic effect of the drug. A high
proportion (over 70%) of embryos however, are unaffected after radicicol and
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geldanamycin treatment at 10 pM, indicating that Hsp90 may be inhibited at a dose that
causes a low level of developmental abnormalities. The possibility remains that the
general developmental defects caused by radicicol treatment are due to specific effects
on Hsp90 clients that are important in basic developmental processes.
Treatment Frequency of defects % Defects
EtOH 6/252 2.4
10 pM Radicicol 114/386 29.5
Untreated 0/94 0
DMSO 10/679 1.5
10 pM Geldanamycin 9/238 3.8
10 pM Geldampicin 11/365 3
Table 3.4: Frequency of general developmental defects (not including fin defects) in WT
embryos after different treatments.
It is also important to consider the defects observed after a heat shock. This allows a
distinction to be made between the defects that are caused by Hsp90 inhibition, and
those that may be caused as a result of the up-regulation of other HSPs by Hsp90
inhibition. Embryos were subjected to heat stress for 30 min to 1 hour, at the same stage
at which an inhibitor would normally be added (See Chapter 2, p50 for details).
Although heat shock was carried out right at the start of gastrulation (60-70% epiboly),
this is a very severe treatment for such early embryos, and should cause a lasting heat
shock response, affecting many aspects of development. All the defects seen after
geldanamycin and radicicol treatment also occurred after heat shock, with the exception
of caudal fin defects, over inflation of the swim bladder and abdomen defects. In
addition, some more severe defects were identified that had not previously been
observed for radicicol or geldanamycin (Figure 3.9). These included pronounced
notochord defects, coloboma and severe eye malformation. The development of more
severe defects after a heat shock than after Hsp90 inhibition, suggests that Hsp90
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Figure 3.9: Developmental defects that arise in sri homozygous
embryos after a 37-40°C heat shock, (a) Neural tube defect; (b) Severe
oedema and growth retardation; (c) Coloboma; (d) Severe oedema and
growth retardation, with eye defect, at higher magnification in (e). Embryos
were scored at 4dpf.
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inhibitors at the levels used did not induce a generalised stress response, although the
possibility remains that a slight induction may have occurred.
The experimental conditions chosen for further testing with mutant zebrafish lines were
concentrations of 10-20 pM geldanamycin and 10 pM radicicol, added at 60-70%
epiboly. Under these conditions, some mild fin defects were observed, as well as a lower
frequency of other defects, survival was over 75% at 5 dpf (compared to over 80% for
EtOH), and eye development was not significantly affected.
3.5 A heat shock response is not induced in embryos treated with a low
concentration of radicicol or geldanamycin
Experiments were conducted to establish whether the developmental defects caused by
the chosen concentrations of radicicol and geldanamycin were a result of Hsp90
inhibition, and not the general stress response that can occur at high levels of Hsp90
inhibition (Zou et al. 1998, Bagatell et al. 2000). Western blotting and RT-PCR were
used to quantify the level of several heat shock proteins that are up-regulated in response
to HSF1 activation by heat shock (Yeh and Hsu, 2002, Lele et al. 1997). Embryos were
treated with inhibitors as described, and harvested after 18h incubation. Where possible,
embryos from a single pair mating were used in each experiment, to prevent
confounding by alterations in HSP levels due to differences in environmental conditions
or developmental stage. To demonstrate the level of induction caused by heat shock,
embryos were incubated at temperatures of 32-37°C for 30-60 minutes before
harvesting.
Quantitative RT-PCR was carried out with primers for Hsp70 and Hsp47. The skeletal
form of actin, a-actin was used as a loading control, as it does not interact with Hsp90,
and therefore should be unaffected by heat shock or Hsp90 inhibition, a-actin should not
be confused with filamentous, or F-actin that does interact with Hsp90 (Kellermayer and
Csermely, 1995). There was no overall difference in the level of Hsp70 and Hsp47
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Figure 3.10: No induction of Hsp70 or Hsp47 mRNA expression by
radicicol or geldanamycin (GA). RT-PCR for (a) WT and (b) sri. DNA
marker is 100 bp ladder, brightest band is 500 bp.
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when compared to untreated controls. A significant increase in the levels of these
proteins could be detected after a heat shock of at least 32°C for 30 min.
Western blotting was carried out using antibodies for Hsp70 (detects inducible form
only) and Hsp90 (detects a and b forms). A duplicate gel, stained with coomassie blue
was used to demonstrate equal loading (not shown). There was a very slight increase in
the level of Hsp90 protein after a 37°C heat shock, and no obvious increase after
inhibitor treatment (data not shown). The antibody used for Hsp70 was unable to detect
the increase in expression caused by a 32°C heat shock, but there does appear to be very
slight increase in Hsp70 levels for both geldanamycin and radicicol compared to a 37°C
heat shock (Figure 3.11a,b).
Staining was also carried out with an antibody for MyoD (Moyogenic differentiation
antigen 1). The binding activity of MyoD is affected by Hsp90 (Shaknovitch et al. 1992,
Shue et al. 1994). As it has been shown in cell culture that Hsp90 inhibitors can cause
the degradation of some Hsp90 client proteins (Marcu et at. 2002, Marcu et al. 2000b,
An et al. 2000, Sakagami et al. 1999, Soga et al. 1998, Schulte et al. 1997), it was
expected that MyoD levels might be affected by Hsp90 inhibition. No change in the
level of MyoD was observed (Figure 3.11c) due either to the stability of MyoD in the
absence of Hsp90, or because the level of inhibition was not high enough to disrupt this
particular interaction.
It can be concluded from these experiments that lOpM radicicol or geldanamycin does
not induce HSP expression at the RNA level. There may be a small induction of HSP
translation, as demonstrated by a slight increase in Hsp70 protein levels. A slight
induction of the heat shock response may have occurred, increasing translation of
Hsp70, but without activating HSF1-mediated transcription of HSPs. Translation of
non-HSP RNAs should therefore be unaffected, allowing development to proceed
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Figure 3.11: A very slight induction in Hsp70 appears to be caused by
radicicol and geldanamycin treatment. Western blotting with Hsp70
antibody for treatment of sri zebrafish embryos with (a) radicicol and
(b) geldanamycin. (c) MyoD.
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amount of induction that may be occurring at a protein level, western blotting should be
repeated several times with a more sensitive antibody, and densitometry analysis carried
out to compare protein levels.
3.6 The frequency of developmental defects caused by Hsp90 inhibition
varies between strains
In treating different zebrafish mutant strains with radicicol (described in Chapter 4, p99)
it was noticeable that the level of certain developmental defects varied between strains.
These results were compiled, and paired analysis of treatment groups and their controls
was carried out for each defect. The difference in frequency of the defect for each pair
was plotted, and ANOVA was used to determine whether the distribution of these
differences varied significantly between strains (Figure 3.12 and 3.13). The difference
was significant for heart oedema and very severe oedema and growth retardation with
reduced pigmentation (statistical calculations carried out by Andrew Carothers). Both of
these phenotypes could be caused by a defect in heart function that causes oedema,
which if severe may cause extensive oedema and growth retardation.
It would be impossible to determine whether this difference in response to the inhibitors
is due to Hsp90 inhibition or to a general toxicity of the drug, unless these experiments
were repeated with a control compound that did not inhibit Hsp90. It would be important
to use a structurally similar compound as a control, to minimise any differences in
metabolism, stability, diffusion, etc.
Defects such as oedema also arise in untreated embryos, and could be caused by any
number of defects affecting the heart or circulation. It would be interesting to identify
Hsp90 buffered modifiers of these less specific developmental defects. This would show
whether response to drugs or acquired disease could be modified by genetic factors, but
only under certain conditions. For example dietary or lifestyle factors might cause a
slight stress response that would uncover these variants.
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Figure 3.12: Frequency of developmental defects for different strains,
treated with radicicol. ANOVA shows whether variation between different
strains is larger than within each strain (p of less than 0.05 is considered
significant). Difference between the frequency of defects for treated and
untreated groups for each experiment is plotted. Data is plotted for each
genotype (y axis). The x axis represents the difference between each pair of
experiments, represented by a dot. A value of zero indicates no difference
between the treated and untreated groups for the experiment.
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Heart oedema p = 0.01






sri hom x hom
sri hom x het
Very severe oedema and growth
Neural tube defects, p = 0.051 retardation, p = 0.003
WIK . . • " • :: —-
dre ' " * * * -- *
mic ; * ' * ' » ♦ *
Tu ' ' -•'**« - ;
sr/'xWIK ' ' •• !
sri hom x hom ;
sri hom x het
, ; .
.03 5 0.000 0.035 0.0/0 0.105 0.1-iC
Figure 3.13: Frequency of developmental defects for different strains,
treated with radicicol, continued.
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It is also worthwhile simply to show that differences in response to drug treatment can
be detected between zebrafish strains. This system could be used to identify genetic
factors that are important in drug metabolism for pharmacogenomic studies. Breeding of
zebrafish is cheap, and uses relatively little space compared to mammalian species,
allowing larger experiments to be carried out. This system has already been used to
detect toxic levels of certain compounds (Schulte and Nagel 1994, Nagel 2002, Roex et
al. 2002).
3.7 Summary and Conclusions
Treatment of WT zebrafish embryos with the Hsp90 inhibitor radicicol reproduced the
phenotype previously reported by Lele et al. for the structurally unrelated inhibitor
geldanamycin, suggesting that this effect is due to Hsp90 inhibition. Radicicol and
geldanamycin caused lethality and developmental defects in a dose-responsive manner.
A concentration of 10 pM radicicol or geldanamycin, for 18h incubations starting from
60-70% epiboly, caused low levels of developmental defects in WT embryos. 10 pM did
not cause a significant heat shock response at the protein or RNA level. Also, the
developmental defects that arose after heat treatment were more severe than for radicicol
or geldanamycin, suggesting that the drugs do not cause a general stress response that
damages development. Novobiocin caused a high frequency of lethality and severe
defects, due almost certainly to effects on topoisomerase II, and demonstrating the
effects of a more toxic drug on development. This work shows that the drugs radicicol
and geldanamycin can be used to inhibit Hsp90 in developing embryos, while causing
very few non-specific morphological defects.
At the concentration of inhibitors used eye defects were extremely rare, so that in
subsequent experiments any eye defects that arise on a mutant background should be due
to an involvement of Hsp90 in the mutant phenotype. The use of two structurally
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unrelated inhibitors will allow the comparison of effects between them, to confirm that
defects observed are due to Hsp90 inhibition and not toxicity. Another important control
is geldampicin, which is structurally related to geldanamycin but does not inhibit Hsp90.
In Drosophila, when Hsp90 function was compromised, many different morphological
defects were observed, which were often specific to certain strains (Rutherford and
Lindquist, 1998). In zebrafish however, the same morphological defects were observed
in different strains. One notochord defect seemed to arise more frequently in one WT
strain (Figure 3.6e). The frequency of this defect was so low that the results were not
statistically significant. Some spawnings however, are more severely affected by Hsp90
inhibition, or show a high frequency of one particular defect even without inhibition,
suggesting that other environmental and genetic effects may influence the outcome of
these experiments. Patricia Yeyati carried out experiments with radicicol in several other
strains, and identified two phenotypes, eye and notochord defects, which arose more
frequently in one particular mutant background when treated with radicicol, and were
enriched in the F2 generation. This shows that Hsp9Q can be used to identify cryptic
mutations in zebrafish. It may be possible to exploit this system to identify milder
mutations in ENU mutagenesis screens.
The differences between morphological defects caused by Hsp90 inhibition in
Drosophila and zebrafish may be caused by several factors. Zebrafish cannot be
completely inbred, as Drosophila can. When a new Drosophila WT isolate was crossed
to Hsp83 mutants, only 0.8% of flies developed morphological defects, while 1.7% of
inbred flies raised on geldanamycin were affected. This suggests that more inbred strains
are more dependent on Hsp90 buffering, presumably because they are more likely to be
homozygous for polymorphisms or mutations. Other reasons for the difference observed
may be due to the relatedness of the strains used, so that although they are not
completely inbred, there was no real variation in the buffered mutations. Although the
lines used for these experiments have been separate for several generations, they were
all on a mixed Tu/AB/TL background.
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Another obvious difference between these two systems is that zebrafish have two forms
of Hsp90, while Drosophila only has one. This may give some redundancy of function,
so that it is more difficult to perturb Hsp90 buffering in zebrafish. There may be other
layers of redundancy and functional stability among the chaperones in zebrafish. The
very nature of Drosophila development, with their imaginal discs that can be so easily
interfered with, may amplify the effects of Hsp90 buffering. Vertebrate development
however, is more complex and there are fewer viable outcomes for each developmental
pathway. This is obvious from an observation of human congenital defects; most are
lethal very early on. Despite these differences, cryptic mutations in eye and notochord
development have been identified, and it may be possible to identify the dose and timing
required to reveal cryptic mutations in other developmental pathways.
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Chapter 4




Investigations were carried out to determine whether Hsp90 buffers developmental eye
defects. This was done because it is evident from clinical data (Schimmenti et al. 1997,
Syagailo et al. 1998, Morrison et al. 2002) and studies in the mouse (Jordan, 1992,
Smith et al. 2000, Chang et al. 2001), that inherited eye malformations can be affected
by multiple environmental and genetic factors. It was hypothesised that among the
zebrafish eye mutants available, Hsp90 would buffer the phenotype of some, and that
this buffering could be revealed by the use of specific inhibitors during development.
Several recessive eye mutants were selected for their weak or variable phenotype. It was
hoped that the homozygotes would be viable and fertile, to allow for easier statistical
analysis of crosses. Initially, homozygous adults were to be crossed to wild types, and
the embryos treated with Hsp90 inhibitors to test whether the penetrance of the
phenotype was altered. Alternatively homozygous embryos could be treated to test for
changes in expressivity. This system was used because it was thought that Mendelian
inheritance patterns would make statistical analysis of any differences in penetrance or
expressivity easier.
4.2 Zebrafish eye mutants
Several zebrafish eye mutants were chosen (by Patricia Yeyati) from among those
generated in the 1996 zebrafish ENU mutagenesis screen at the Max-Planck Institute for
Developmental Biology, Tubingen (Table 4.1, Development, volume 123, 1996). This
screen identified recessive and usually homozygous lethal mutations with defects in
specific organs. The mutants chosen were reported as being either viable or semi viable
(Haffter et al. 1996). All of the mutants selected, except sandy, had previously been
complementation tested, and found to be complementary (non-allelic) with respect to
each other (Heisenberg et al. 1996).
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ENU mutagenesis had been carried out on Tubingen (Tii) wild type males that were then
crossed to AB, TL, or a Tu:AB hybrid strain (Table 3.2). All the lines ordered were
out-crossed to Tu or TL to produce the embryos that were shipped to our fish facility in
Edinburgh and raised to adulthood. TL is homozygous for the mutations, led1 and lof'2.
led1, also called tup or Brachydanio frankei, is recessive and gives spots in the
homozygous adults, while lof'2 is dominant and gives long fins (Haffter et al. 1996).
These two mutations are non-deleterious, and are used to aid the identification of adults
when carrying out pair mating.
Mutant Allele Phenotype Viability References Phenotype
visible (dpf)
sunrise (sri) tq253a Prominent lens, irregular
cornea.






tm329 Slightly reduced body
size, Small eyes,
expanded melanopores,




rosine (rne) tm70h Small lens adult viable Heisenberg et al.
1996.
4
dreumes tm146d Reduced body size, small adult viable Heisenberg et al. 4

























Table 4.1: Phenotypic characteristics of zebrafish mutants chosen from the 1996 ENU
mutagenesis screen (http://www.zfin.org).
Heterozygous F1 adults were identified by inter-crossing and comparison of any
suspected eye defects with those published for the mutant. The expected phenotypes
were observed for sri, mic, and dre, except the subtle ear defect described for dre
(Whitfield et al. 1996), as the ears were not examined at high magnification (Figure 4.1).
Non-closure of the optic fissure, (coloboma) arose at a low frequency for both sri and
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Figure 4.1: The homozygous phenotype observed for the zebrafish
eye mutants at 5 dpf. (a) sri; (b) mic; (c) dre; (d) WT.
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dre. The frequency of embryos showing the homozygous phenotype should be 25% for a
heterozygous cross if the phenotype is fully penetrant. The observed frequency for each
mutant was tested for deviation from the expected 25% with a two-tailed Fisher's exact
test (Table 4.2). The proportion of sri mutants scored was significantly smaller than the
25% expected, showing that the mutation is either not fully penetrant or that the milder
defects in some homozygotes cannot be detected by examination of live embryos
(Chapter 2.5, p50).
Embryos
Mutation Mutant WT Total % mutant p value
sri 131 500 631 20.7 0.0001
mic 262 816 1078 24.3 0.698
dre 162 425 587 27.6 0.3212
Table 4.2: Frequency of the mutant phenotype in heterozygous in-crosses, showing the Fisher's
exact test p value. A p value of 0.05 (5%) is considered significant.
A phenotype was not observed for rne, either due to difficulty of scoring the subtle
defect, lack of carriers in the surviving adults, or silencing by modifiers in the outcross
received, sdy and hez did not survive transportation well, and the phenotype was not
observed from crosses of the few adults that remained. These three mutants were not
used for further studies.
Homozygous embryos from sri, mic, and dre were kept and raised, sri adults were viable
and fertile, while dre failed to thrive and were humanely killed, mic did not survive
beyond two to three weeks, possibly due to a failure of the swim bladder to inflate, or
inability to feed due to blindness.
4.3 Treatment of heterozygous zebrafish eye mutants with Hsp90
inhibitors
Experiments were conducted to determine whether a mutant phenotype could be induced
by Hsp90 inhibitor treatment of heterozygotes for each of the eye mutants. Heterozygous
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embryos were collected from crosses between a WT and a heterozygous or homozygous
mic or sri fish, and treated with radicicol (Chapter 2.3, p49). No eye defects were
observed in the treated embryos, apart from the small eyes previously described in
oedematous embryos (Chapter 3.4.4, p83). Embryos from dre heterozygous crosses were
treated in the same way. There was a decrease in the frequency of embryos showing the
dre phenotype, presumably due to a higher sensitivity of the homozygous embryos to
radicicol treatment. There were no mild eye defects among the rest of the treated
embryos that could suggest that a slight mutant phenotype had been induced in the
heterozygotes.
Mutant embryos
Mutant Cross % Epiboly at start
of treatment
pM radicicol Treated Untreated
mic WT x het 30-50% 2.5-3 0/362 0/27
mic WT x het 60-70% 10-20 0/80 -
mic WT x het 80-90% 15-25 0/61 -
sri WT x het 30-50% 0.1-2.5 0/181 0/98
sri WT x het 60-70% 10-20 0/91 -
sri WT x horn 60-70% 10-20 0/279 0/50




Table 4.3: Frequency of embryos showing the mutant phenotype in radicicol treated
heterozygotes.
It was hypothesised in Chapter 1.6 (p44) that Hsp90 may stabilise or buffer
developmental processes, either directly or indirectly. In mutants buffered in this way,
reduction of Hsp90 function could be expected to increase the penetrance of the
phenotype. For the majority of genes, loss of function of one allele does not cause a
dominant, or haploinsufficient phenotype (Wilkie, 1994). It was expected however, that
Hsp90 might buffer some developmental regulatory pathways to an extent that in
individuals haploinsufficient for one component of the pathway (heterozygous for a
recessive mutation), the morphological outcome would be more vulnerable to Hsp90
inhibition. These results show that Hsp90 inhibition, under the conditions used, is not
enough reveal the mutant phenotype in embryos heterozygous for the recessive
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mutations sri, dre and mic. It appears, therefore, that a developmental pathway can be
relatively robust, despite the presence of a Mendelian mutation.
There may still be several ways to cause a visible eye phenotype in these heterozygotes.
Homozygotes for these mutations have a variable phenotype, indicating that other
genetic or environmental factors are important in determining the severity of the
phenotype. If the most affected embryos were selected over several generations, genetic
modifiers that amplify the phenotype may accumulate, so that the pathway containing
the mutation might be more vulnerable to Hsp90 inhibition in heterozygotes.
Alternatively, if treatment was initiated at 10-11 hpf, immediately before the start of eye
development, it might be possible to avoid affecting the more general developmental
processes such as gastrulation and the onset of somitogenesis. In humans, eye
development is the most vulnerable to teratogens between 3 Vi to 12 weeks. During this
time, the eye is continually developing (Moore, 1998). Therefore, if radicicol was added
even later, after 11 hpf, this may also have a significant effect on eye development. This
later treatment could allow a much higher dose of radicicol to be used, which would be
more likely to have an effect on heterozygotes.
4.4 Treatment of homozygous zebrafish eye mutants with Hsp90 inhibitors
Experiments were conducted to determine whether the expressivity of the homozygous
mutant phenotype could be affected by Hsp90 inhibition in zebrafish eye mutants. This
was done because although the mutations revealed in Drosophila and Arabidopsis were
cryptic (Rutherford and Lindquist, 1998, Queitsch et al. 2002), modulation of a fully
penetrant but variable mutant phenotype by Hsp90 inhibition would demonstrate that
Hsp90 buffers the effects of the mutation. For each mutant, embryos from either a
heterozygous or homozygous cross were treated with Hsp90 inhibitors, and scored
according the criteria described below. Part of each spawning was treated with the
carrier solvent only, as a control (Chapter 2.3, p49).
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4.4.1 Measurement of the severity of mutant eye phenotypes
The severity, or expressivity, of the sri and dre mutant eye phenotype is variable. The
most obvious variables for sri were the irregularity of the cornea, lens and pupil. The
extent of pupil irregularity was also variable for dre (4.2a). It was important to establish
a method for scoring each phenotype, so that the effect of Hsp90 inhibition on
expressivity could be quantified. First, the presence or absence of coloboma was scored.
Secondly, for some experiments, digital photographs were taken of each eye, and a line
drawn around the pupil and outer edge of the retina. Measurements were then taken of
the area, major axis, eccentricity (irregularity) and standard deviation of the radius (SD
radius, a measure of ellipticity) of the pupil and the outer edge of the retina (Figure
4.2b). A t-test was used to calculate the significance of the difference between the means
(Chapter 2.4, p50)
The sri phenotype varied so widely that it was possible to develop a numerical score
based on qualitative scoring of the extent of irregularities in the cornea, lens and pupil
that could be scored by eye using a dissection microscope. Each eye was scored into one
of three categories, and a numerical score was given to the embryo based on the score
for both eyes (Table 4.4, Figure 4.2c). Embryos were scored twice, and if a phenotype
was on the borderline between two categories it was put into the lower of the two.
Embryos with an AC score were given a numerical score of 2. A mean severity score
was then calculated for each treatment group (bars in Figure 4.4). Significance of the
differences between treatment groups for several experiments was calculated, using the








Figure 4.2: Quantification of the severity of zebrafish eye phenotypes.
(a) Variability of the dre phenotype; (b) Measurement of the size and shape
of the pupil and outer edge of the retina; (c) Severity categories for the sri
phenotype and allocation of a numerical score to each embryo based on the
severity in each eye.
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A) Mild B) Intermediate C) Severe
Lens Must be regular and close
to normal width, can be
slightly protruding
Must be at least half of
normal width, must be
irregular/smaller/sunken if
pupil is regular
Must be less than half normal
width if coloboma is absent
Cornea Must be irregular Can be extremely irregular Can be extremely irregular
Pupil Must be regular, can be
slightly smaller
Must be irregular if lens is
regular
Coloboma must be present if
lens is more than half normal
width, or may be almost closed
if lens is less than half normal
width
Table 4.4: Categories for scoring the sri phenotype.
4.4.2 WT
Eye defects were extremely rare in WT embryos treated with 10 jaM radicicol or
geldanamycin (Chapter 3.4.4, p83). However, segment analysis showed that the eye is
slightly smaller in radicicol treated embryos compared to untreated embryos from the
same spawning. Both the area and major axis were significantly reduced for the pupil
and retina (Table 4.5). A reduction in eye size may be connected to the general
developmental retardation observed at 1 dpf. By 5 dpf, there may still be a slight
developmental delay in either the whole embryo or just the eye.
Area Major axis SD radius Eccentricity
Strain Treatment n pupil retina pupil retina pupil retina pupil retina
WT EtOH 85 6486 16528 182 463 4.47 7.15 0.40 0.50
radicicol 72 6147 16204 172 458 4.58 7.06 0.40 0.50
sri EtOH 177 2906 10363 86 292 6.51 6.88 0.44 0.50
radicicol 180 2465 9669 77 276 9.80 7.48 0.56 0.53
dre EtOH 158 5599 16405 159 467 7.16 8.46 0.51 0.56
radicicol 177 5445 16054 154 459 6.85 8.63 0.48 0.56
b) Area Major axis SD radius Eccentricity
Strain pupil retina pupil retina pupil retina pupil retina
WT <0.001 0.021 <0.001 0.1342 0.5946 0.341 0.931 0.746
sri <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
dre 0.023 0.001 0.0046 0.0002 0.1332 0.2802 0.035 0.164
Table 4.5: Segment analysis of the pupil and retina, showing mean values (a) and p value for
the difference between means for EtOH and radicicol (b). A p value of less than 0.05 (5%) is
significant.
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There may also be a specific effect of radicicol on eye development that causes a very
mild reduction in the size of the eye. Under non-stress conditions, Hsp90b is highly
expressed in many regions during development including the eye, from at least 16 hpf
(Lele et al. 1999, Figure 4.3). Studies in mammals have also shown dynamic expression
of Hsp90 in different regions of the eye during development (Tanaka et al. 1995, Kojima
et al. 1996, Dean and Tytell, 2001). It is not surprising therefore, that a low level of
Hsp90 inhibition may have an adverse effect on eye development. It has already been
established however, that at concentrations of 10 pM or less, morphological eye defects
are extremely rare, and there was no obvious increase in the pigmentation of embryos
that would accompany blindness. Therefore although this reduction in eye size has no
apparent deleterious effects on eye development, it should be taken into account when
considering the effects of radicicol on eye mutants.
4.4.3 sunrise
sri homozygotes were treated with radicicol and scored by all three of the methods
described in Chapter 4.4.1 (pl04). An attempt was made to carry out the qualitative
scoring blind, but this was only possible for geldanamycin, as the particular fin defects
caused at a high frequency by radicicol made the treated groups easy to identify.
A significant increase in the mean severity score was observed for 10 pM radicicol,
10 pM geldanamycin, and heat shock (37-40°C, 1 h), but not for geldampicin, compared
to untreated controls (Figure 4.4). These results were reproduced for radicicol by
segmentation analysis, which showed an increase in eccentricity and SD radius of the
pupil and retina. The reduction in area and major axis was also larger than for the WT,
showing an additional effect of radicicol on the size of the eye and pupil in sri (Table
4.4). There was a significant increase in the frequency of coloboma, from 2.7 to 8.3%
(Fisher's exact test, p value 0.0209). This shows that the severity of the sri phenotype is
increased by Hsp90 inhibitors, and that Hsp90 modulates the expressivity of the sri
mutation.
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Figure 4.3: Expression of Hsp90 in the zebrafish lens at 20 hpf
(Reproduced from Leieetal. 1999).
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Figure 4.4: Mean severity score for sri treated and control groups,
(a-c) A significant increase in the mean severity score of the sri phenotype
was observed for (a) radicicol, (b) heat shock and (c) geldanamycin. (d) No
significant increase was observed for geldampicin. Blue bars (untreated
group), red bars (treated group). Each pair of bars represents one
experiment, t and p values for a combined significance of the difference
between treated and untreated groups for each treatment type are shown.
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The effects of radieicol and geldanamycin were dose-responsive, so that a lower
concentration of radicicol (4-8 jiM) caused a lower increase in severity (t 2.53, p 0.01,
by qualitative scoring). A higher dose of geldanamycin (15-20 uM) also gives a larger
increase in severity (t 5.58, p 0), but preliminary western blot analysis for concentrations
of geldanamycin over 10 |iM showed an increase in Hsp70 levels, so that this increase
may not be due solely to a decrease in Hsp90 function (data not shown)
The increase in the severity score was more significant for radicicol than geldanamycin
when they were both used at 10 pM. This difference is almost certainly due to the
difference in the Hsp90 binding affinity of these two drugs (Roe et al 1999). The largest
increase in severity was observed for heat shock. At this temperature, general protein
damage may occur that diverts Hsp90 activity, compromising its normal functions more
than pharmacological inhibition alone. Activation of the heat shock response will also
have other more general adverse effects on eye development, due to down-regulation of
translation and induction of HSPs, especially in embryos made vulnerable by mutation.
The embryos most severely affected with respect to the eye phenotype were also more
affected with respect to other defects. The other defects were ranked according to
severity (Table 4.6). Severity of the eye trait was significantly correlated to the severity
of other defects, with a Pearson correlation value of 0.261, which gives a p value of less
than 0.01 (Figure 4.5, statistics carried out by Andrew Carothers). All the embryos in
one dish should be subject to the same environmental conditions, but there may be small
variations in concentration of the drug or cleanliness of the water that affect the severity
of the phenotype. Alternatively there may be genetic factors that affect susceptibility to
Hsp90 inhibitors, which affect development as a whole. Genetic factors may include
"housekeeping" proteins, such as p53, that interact with Hsp90 (King et al. 2001). They
may also include proteins involved in the uptake or metabolism of the drug, such as
cytochrome 450 (Reviewed in Rogers et al. 2002). Variation could also simply be
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Severity of other defects
Figure 4.5: The severity of the sri phenotype is correlated to the
severity of other defects (Andrew Crothers).
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"developmental noise" caused by slight random variations in developmental pathways
that confer susceptibility to Hsp90 inhibition (Rutherford and Lindquist, 1998,
McAdams and Arkin, 1999).
Score Severity Defect
0 Unaffected None detected
1 Slightly affected Small part of caudal fin missing
2 Very mild Half of caudal fin missing
3 Mild Nearly all of caudal fin missing
4 Moderate Heart oedema
5 Severe Growth retardation, bends or any other body
defect.
6 Very severe Very severe oedema with growth retardation,
reduced eye size and reduced pigmentation.
Table 4.6: Ranking of developmental defects, not including any specific eye phenotypes.
4.4.4 dreumes
Treatment of dre het x het crosses with radicicol gave no obvious increase in any of the
traits measured (Chapter 2.4, p49) in the homozygous embryos, apart from the area and
major axis, which are observed in the WT. Statistical analysis however showed that the
area of the lens was less significantly reduced than in the WT, while the retina was more
affected (Table 4.4). There was also a marginally significant reduction in eccentricity of
the pupil. The frequency of coloboma is reduced, although not significantly (3.3%
untreated, 0.4% treated, Fisher's exact test, p 0.1437). Frequency of coloboma was also
slightly reduced after heat shock (11.1% untreated, 7.1% treated, p 0.2884). Therefore
the homozygous phenotype for dre appears to be slightly improved, perhaps through
effects on the retina. This change is not unexpected, as Hsp90 may buffer any kind of
mutation that destabilises protein structure. This could include negative regulators that,
when buffering is released, allow the phenotype to improve.
4.4.5 microps
mic homozygotes did not survive well after radicicol treatment, so that severity of the
phenotype could not easily be scored. From heterozygous crosses, only 16% (27/173)
homozygotes survived, while 28% (56/200) homozygotes were present in the untreated
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controls. As mic embryos do not survive very long even without treatment (up to
approximately 14-21 dpf), it is likely that Hsp90-dependent developmental processes
that are weakened by the mic mutation are further weakened when Hsp90 function is
compromised. It would be interesting to treat these embryos at a lower concentration of
radicicol to test for effects on severity of the eye phenotype.
4.5 Summary and conclusions
Treatment of the recessive eye mutants sri, mic and dre, resulted in very different
outcomes. It was not possible to induce a mutant phenotype in heterozygotes for any of
the mutants. When homozygotes were treated, this resulted in increased lethality of mic,
a worsening of the phenotype in sri, and a slight improvement in the phenotype for dre.
The most prominent feature of the sri phenotype is the lens, which is reduced even in
mildly affected embryos. All of the retinal cell layers appear to be present, but slightly
disorganised, perhaps due to a reduction in pressure caused by a smaller lens (Figure
4.6a, Chapter 5.6, pl38). It appears, therefore, that the phenotype is primarily caused by
the lens. Hsp90 is strongly expressed in the eye, including the lens, so that it could be
involved in buffering a lens-specific phenotype. It is unlikely that the mutated protein
binds Hsp90, as the Hsp90 client proteins are largely metastable signalling proteins and
transcription factors, none of which is likely to give a specific morphological defect
when mutated (Reviewed in Picard, 2003). Also, if Hsp90 did interact directly with a
mutant protein the effect of Hsp90 inhibition would be expected to be larger. It is
possible that the mutation is up or downstream of a factor that does interact with Hsp90,
and is in turn affected when Hsp90 function is compromised. It is difficult to predict
which proteins could be important, as lens development is complex, and the Hsp90
client proteins are involved in multiple signalling pathways.
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Figure 4.6: Lens defects in zebrafish eye mutants, (a) s/7; (b) dre.
Untreated embryos were sectioned at 5 dpf.
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One obvious candidate Hsp90 client that could affect lens development in sri is the
inducible form of Hsp70. From investigation of Hsp70 expression in the in chicken lens,
it has been suggested to have a role in differentiation of the lens fibres (Dash et al.
1994). Hsp70 is highly expressed in the zebrafish lens from 28 to 42 hpf (Blechinger et
al. 2002b, Halloran et al. 2000, Figure 4.7a), during which time the lens starts to
differentiate (Easter and Malicki, 2002). Expression of Hsp70 is therefore initiated at a
time when the inhibitor was usually rinsed out (from approximately 26-29 hpf), so it
may have been affected at a critical stage in the onset of differentiation. Overexpression
or increased activity of Hsp70 due to Hsp90 inhibition might have a deleterious effect on
lens differentiation. Also, activation of Hsp70 earlier than 28 hpf might have serious
effects on the initiation of differentiation. Hsp70 may also be one of the factors that
exacerbates the sri phenotype after heat shock. Heat treatment could cause protein
damage that would sequester Hsp70 and affect lens development, as well as the effects
on the timing and level of expression already mentioned.
Another HSP that may be important in the effects on sri may be the collagen binding
protein, Hsp47, which is also expressed in the developing zebrafish eye (Lele et al.
1997b). Several types of collagen are known to be important in lens development
(Savontaus et al. 1997, Kelley et al. 2002). Hsp47 is strongly expressed in the lens from
approximately 19-42 hpf (Thisse et al. 2001, Figure 4.7b), and timing of expression
therefore also coincides with the differentiation of the lens. Hsp47 is strongly
upregulated after heat shock, and may play an important role in the effects of heat shock
or Hsp90 inhibition on the sri phenotype.
The worsening of the sri phenotype observed after radicicol treatment might therefore be
caused by effects on Hsp70 and Hsp47 translation, due to induction of a heat shock
response. It was mentioned in Chapter 3.5 (p87) that Hsp70 is mildly induced by
radicicol and geldanamycin, and Hsp47 could be expected to behave in the same way.
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36-42 hpf 42-48 hpf 48-60 hpf
Figure 4.7: Expression of HSP mRNA during zebrafish development.
(a) Whole-mount in-situ hybridisation analysis of Hsp70, showing the expression
pattern for heat shocked (first column) and control embryos (second two columns),
and in sections of control embryos (P and Q). Hsp70 is expressed in the lens from
28-42 hpf under normal (control) conditions, and strongly expressed throughout the
embryo after heat shock (Reproduced from Blechinger et al. 2002b); (b) Whole-
mount in-situ hybridisation analysis of Hsp47, showing strong expression in the
lens from 19-42 hpf. (Reproduced from Thisse et al. 2001).
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Although Hsp70 and Hsp47 are only expressed in the lens, there is ample evidence that
the lens is important for development of the retina and other structures of the eye (Kurita
et al. 2003, Ashery-Padan et al. 2000, Collinson et al. 2001). These proteins may also
explain the reduction in size of the pupil and retina in radicicol treated WT embryos.
Work carried out by Auluck and Bonini (2002) in Drosophila has shown that even in the
absence of a detectable increase in Hsp70 protein levels, there is evidence for Hsp70
protein activation after geldanamycin treatment. The slight induction observed in
translation may therefore be indicative of a larger induction of Hsp70 activity.
Comparison of the dre and sri phenotypes in more detail however, shows that the effects
of Hsp90 inhibition on sri is not a general effect on all lens mutants. Both sri and dre
have an irregularity in the anterior part of the lens, and discolouration that is
characteristic of cataracts (Figure 4.6). If activation of Hsp70 were the major factor in
modulation of the sri phenotype by Hsp90 inhibition, it would be expected that dre
should respond in the same way. Hsp90 inhibition, however, affects these two eye
phenotypes in different ways. This shows that the response of mutant phenotypes to
Hsp90 inhibition depends upon the specific gene that is mutated, and the developmental
processes that are affected by it.
The difference in response of the sri and dre phenotypes to Hsp90 inhibition suggests
several conclusions. The smaller difference caused in dre compared to sri shows that
different mutations rely to differing extents on Hsp90 buffering. During Hsp9Q inhibitor
treatment, the sri phenotype is most likely aggravated by the disruption of a vital
developmental process. In dre there may be a modifier that regulates the mutated
protein, or a factor closely related to it, that is stabilised by Hsp90, and which worsens
the mutant phenotype. When Hsp90 is inhibited, degradation or loss of function of this
modifier may alleviate some of the damage caused by the mutated protein. An example
of this type of mechanism was observed in Drosophila eye development.
In Drosophila the serine/threonine kinase Raf is required for the signalling pathway that
activates the sevenless receptor tyrosine kinase. Sevenless activation is essential for the
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development of R7 photoreceptors (Raabe, 2000). Raf interacts with Hsp83 (Hsp90),
and mutations in Hsp83 have been identified in two independent screens for modifiers of
an R7 mutant phenotype (Cutforth and Rubin 1994, van der Straten et al. 1997). In one
screen a mutant was used in which Raf was constitutively activated, causing an increase
in the number of R7 photoreceptors. Dominant suppressor mutations were identified,
including some hypomorphic alleles of Hsp83 (van der Straten et al. 1997). In another
screen, a hypomorphic allele of sevenless was used to identify dominant mutations that
further reduced R7 photoreceptor development. In this screen Hsp83 hypomorphic
alleles also impaired signalling by sevenless, but had the opposite effect on R7
differentiation (Cutforth and Rubin 1994). These two experiments together give an
elegant example of how a reduction in Hsp90 function can cause opposite effects on the
developmental outcome of the same signalling pathway.
Raf signalling is also important in development of the retina and lens in mammals
(Hecquet et al. 2002, Zatechka et al. 2002a, Zatechka et al. 2002b), and given the
conservation in development observed between zebrafish and higher vertebrates, this is
likely to be conserved in zebrafish. Raf may therefore be part of the mechanism involved
in the effects of Hsp90 inhibitors on sri and dre.
These results show that Hsp90 is involved in modulating the expressivity of mutant
phenotypes in vertebrates. This has important implications for the human developmental
eye diseases with variable expressivity mentioned in Chapter 1.1 (pl9). Individuals
carrying mutations in genes such as Pax2 or Shh may be affected by environmental
factors during development that influence the function of Hsp90. Environmental factors
affecting Hsp90 might include dietary intake and other lifestyle factors, or toxic
chemicals. Serious eye defects could therefore be prevented by controlling these factors
in families with a known history of inherited eye disorders.
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Chapter 5




The sri mutation was mapped in collaboration with Ralf Dahm and Robert Geisler
(Max-Planck Institute for Developmental Biology, Tubingen, Germany). It was
undertaken to allow a better understanding of the mechanism by which Hsp90 buffers
the sri phenotype. It was expected that knowledge of the mutated protein would
facilitate identification of factors up and down-stream in the developmental pathway,
and show which Hsp90 clients might be important.
5.2 Linkage mapping of the sri mutation
sunrise was identified as part of an ENU mutagenesis screen for recessive mutations that
affect specific aspects of organogenesis (Haffter et al. 1996). The sri mutation was
mapped by linkage analysis. In this method, PCR analysis with polymorphic markers is
carried out on groups of embryos showing the homozygous mutant phenotype, and their
unaffected sibs. Primers are used that amplify regions containing microsatellites, or
Simple Sequence Length Polymorphisms (SSLPs). SSLPs are CA repeats that vary in
length (polymorphic) in populations, but have no deleterious effect. Variation in the
length of these repeats can be visualised by agarose gel electrophoresis. In pools of
embryos, the intensity of the different size bands relates to the frequency of each
polymorphism in the population of embryos. Bands are identified that are more intense
for the mutant pool. These markers are closer to the mutated site, with a lower frequency
of separation from the mutation by meiotic recombination. This recombination
frequency can translated into a genetic distance, known as the linkage distance, in
centimorgans (cM) or centirays (cR) (Strachan and Read, 1996, Geisler, 2002). One
centimorgan in zebrafish is roughly equivalent to 660 Kb, or approximately 16 cR
(Geisler, 2002). Once a rough map position is obtained, single embryos can be used to
map the mutation more accurately. The location of the markers on existing genetic maps
can be used to locate candidate genes within this region, to be screened for mutations.
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To ensure that the fish will be polymorphic for the markers used, the mutant strain to be
mapped must be crossed to an unrelated wild-type strain that is relatively out-bred, sri
homozygotes were crossed to the out-bred wild-type strain, WIK (Rauch et al. 1997,
Nechiporuk et al. 1999, Table 3.3). The F1 was raised, and pools of F2 embryos
showing the mutant phenotype and their WT sibs were collected and fixed, before
shipping (Figure 5.1a). It was very important to identify the mutant and WT phenotypes
correctly, so as to allow calculation of an accurate map position. It was particularly
important to avoid scoring WT embryos as mutants (false positives). The variability of
the sri phenotype made identification of mildly affected embryos difficult, and many
embryos showing a very slight mutant phenotype were discarded. DNA extraction and
linkage analysis was carried out by Ralf Dahm and Helia Schonthaler using markers for
the Boston MGH map (Knapik et al. 1998).
The rough map position for the sri mutation was between 29.7 and 33.2 cM from the top
of linkage group 7 on the MGH map (667 to 723 cR on the T51 radiation hybrid map),
between markers z20963 and z 11085. The map viewers on the ZFIN and NCBI websites
were used to identify genes contained in this region, among which the most promising
candidate was Pax6b (Figure 5.1b). Intronic primers for exons 1 and 6 of Pax6b were
designed using the Pax6b genomic sequence from the Sanger Centre zebrafish
whole-genome shotgun sequencing project (complied and annotated by Philippe
Gautier). These were used by Ralf Dahm and Helia Schonthaler to map Pax6b onto the
T51 radiation hybrid mapping panel that was used as a reference for the mapping
markers. The map position of Pax6b was closest to the marker fc33g08 at 684 cR on
linkage group 7 inside the region containing the sri mutation (this marker is not part of
the Pax6b sequence).
5.3 Identification of a point mutation in the sri candidate gene Pax6b
Based on the rough map position and what is known about Pax6 haploinsufficiency
































Figure 5.1: (a) Linkage mapping. Adults carrying the mutation are crossed
to an unrelated WT strain. The F1 are crossed, and pools of mutant and
unaffected sibs are collected. PCR is carried out with polymorphic markers.
Markers that give bands which are more intense in the mutant than the sib
pools are linked to the mutation (Reproduced from Geisler, 2002);
(b) Rough map location of the sri mutation. Linkage group 7, showing
the 56 cR (2.5 cM) region containing the sri mutation, and the position of
Pax6b as confirmed by radiation hybrid mapping.
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for the sri mutation. ENU usually causes point mutations, the most common of which
are AT to TA transversions, and AT to GT transitions (Reviewed in Balling, 2001).
These could cause missense or truncation mutations, and possibly splice-site defects.
RT-PCR was carried out to identify any differences in the length of the cDNA. The PCR
product for sri appeared to be the same length as the WT (data not shown). The coding
region of sri Pax6b was then sequenced to identify any nucleotide changes that could be
expected to disrupt the function of the protein.
The Pax6b cDNA from sri and WT embryos was RT-PCR amplified and sequenced in
several sections. The sequence was compared to the published Pax6b cDNA (NCBI
Genebank reference number NM_131641 at http://www.ncbi.nlm.nih.gov/, Nornes et al.
1998). Five changes were identified in the sri coding sequence, and four in the
3' untranslated region (UTR) (Figure 5.2, Table 5.1). Three of the nucleotide changes in
the coding sequence were synonymous, causing no alteration in the amino acid
sequence. These variants were also present in the WT sequence from Tu/AB/TL
embryos (Table 3.3).
Coding 3' UTR
Variation 429 A>C 989 G>A 991 T>C 1304 A>C 1586
insCTT
1600 G>C 1611 C>G 1650 A>G
Published A G T A G C A
cDNA
sri C A C C insCTT G G G
WT AIC G/A T A/C insCTT G/C C/G A/G
Table 5.1: Nucleotide variations identified in WT and sri Pax6b cDNA, with respect to the
published cDNA sequence NM_131641. The mutation is shown in red.
Polymorphisms are relatively rare in mammalian Pax6; nearly all nucleotide changes are
deleterious (Reviewed in Prosser and van Heyningen, 1998). Only two synonymous
changes have been reported in humans, both of which are outside the most conserved
regions, the paired domain (PD) and homeodomain (HD) (Davis and Cowell, 1993,
Brown et al. 1998, Grpnskov et al. 1999, Pax6 database at http://pax6.hgu.mrc.ac.uk). It
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991 T rGRGRRRGR GTTTGRRRGR RCRCRCTRTC CRGRCGTTTT CGCRRGRGRG RGRCTTGCGG CRRRRRTTGR CCTCCCGGRR GCRRGflflTRC
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108l^GGTCTGGTT TTCRRRCRGR RGRGCCRRGT GGRGGRGRGR GGRGRRRCTG RGGRRCCRGR GRCGRCRRGC CRGCRRCTCC TCCRGTCRCR
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1171 TTCCCRTCRG CRGCRGCTTC RRCRCCRGCG TCTRTCRGGC CRTCCCRCflfl CCCRCCRCRC CTGTGTCCTT CRCGRCRGGC TCRRTGCTGG
I P I s S S h NTS U Y Q R Inp Q P T T P U S F T T G S M L
GCCGRCCRGR CRCRGCTCTG RCCRRCRCRT RCACGGGTTT RC(j RpCRRTG CCCRGCTTCR CTRTGGCCRR CARCCTGCCT RTGCRRCCflfl
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1351 GCCRGRCRTC TTCCTRTTCC TGCRTGCTGC CCRGCRGTCC GTCRGTGRRC GGGCGRRGCT TCGRCRCTTR CRCCCCCCCT CRCRTGCRGG
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5 Q T S S Y S C M L P S S P SUN G RS FDTY TPP HMQ
1441 CflCRCRTGflfl CRGCCflflflCT RTGGCCRCTT CTGGCRCCGC TTCCRCRGGR CTCRTCTCTC CTGGRGTGTC TGTCCCTGTC CRRGTCCCCG
I
RHMN SUT MAT SGTR STG L





GTEP BHS QY Wi-i S R L Q
1621 GflflGCTGGBC GCGTCTGCRC flGTBTTTCIH CflCRCfiGflCT CRfiflCflRRCT GTCRTRRGGR TGRGGCGC
Figure 5.2: Pax6b cDNA, showing region amplified by RT-PCR and
sequencing (NM_131641 Reproduced from www.ncbi.nlm.nih.gov). Sites of
nucleotide polymorphisms are highlighted in red, and the missense
mutation in green.
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was therefore unexpected to find so many changes in Pax6b, especially as one is in the
PD, and two are in the HD. The variants described in Table 5.1, as well as two others,
were identified in the sequence released from the Sanger Institute (gi 31455425). This
confirms that they are not merely sequencing errors on my part. The strain used for the
published sequence may be different from those used for sri sequencing, and therefore
contain different polymorphisms. The WT and sri embryos were on a Tii/AB/Tl
background, and Tti and AB were used at the Sanger Institute, but the strain used by
Nornes et al. for the cDNA sequence NM_131641 was not stated. It has been found
when assembling the zebrafish genome sequence that the frequency of variants is at least
l/200bp (Sanger centre, 2003). The presence of two copies of many genes may allow
sequence changes to occur without causing a reduction in fitness.
One non-synonymous change in the sri sequence was identified; a T to C transition in
exon 8, at position 991 in the cDNA, that changes the amino acid leucine to a proline in
the HD, and is therefore a missense mutation (Figure 5.3). This mutation was also
identified when exon 8 was amplified from the genomic DNA. A G to A variant is
almost immediately adjacent, at position 989, and the same haplotype is always
observed for these two changes, as expected for two such closely linked variants,
The mutation 991 T>C creates a Ddel digestion site (Figure 5.4a). This was used to test
whether the mutation was present at the expected frequency in individual embryos from
a sri het x het mating. Genomic DNA was made from individual embryos, and exon 8
was PCR amplified and digested with Ddel (Figure 5.4b). The ratio of
WT:heterozygous:homozygous did not deviate significantly from the expected
frequency of 1:2:1, with a Chi square (E2) value of 1.390, showing that the deviation
observed is not significant, with a p value of 0.499 (Table 5.2). A band of approximately
70 bp was identified in WT and heterozygous digests. Sequencing identified two linked
polymorphisms in intron 7 that create another Ddel digestion site, linked to the WT
Pax6b allele (Figure 5.4c).
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Figure 5.3: A missense mutation in Pax6b of sri. Sequencing traces,
showing the T>C mutation in Pax6b genomic DNA from sri homozygous,
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Figure 5.4: (a) A Ddel site (ctnag) is created by the 991 T>C mutation
(triangle indicates position of incision; (b) Ddel digest, showing the difference
in restriction sites caused by the sri mutation, and an additional band at 70 bp
in the WT and heterozygote; (c) Presence of polymorphisms in intron 7,
creating an additional Ddel restriction site (red). Thicker line represents exon.
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WT Heterozygous Homozygous
Observed 7 23 11
Expected 10.25 20.5 10.25
Table 5.2: Ratio of genotypes for Ddel digestion of het x het embryos.
5.4 Pax6 structure and function
Pax6b is an orthologue of Pax6, a member of the Pax transcription factor family, of
which there are nine members in humans and mice. The Pax proteins are defined by the
presence of a paired domain (PD), which is involved in sequence-specific DNA binding.
The Pax proteins are involved in organogenesis, and mutations in these can cause severe
morphological abnormalities (Reviewed in Chi and Epstein 2002, Pichaud and Desplan
2002) Studies of the Pax6 mutants; aniridia in humans, Small eye (Sey) in mice, and
eyeless (ey) in Drosophila, have provided a large body of information regarding the
function of Pax6 in development (Simpson and Price 2002). Pax6 has been described as
a "master-regulator" of eye development, largely due to its capacity to induce eye
development when expressed in Drosophila imaginal discs (Haider et al. 1995).
Pax6 also contains a paired-like homeodomain (EDD), which is linked to the PD by a
glycine-rich linker, and a C-terminal transactivation domain, also known as the PST
domain because it is rich in proline, serine and threonine (Figure 5.5a). The function of
the Pax6 protein is complex, both the PD and HD are thought to be involved in DNA
binding, as well as binding to other proteins (Planque et al. 2001), and have been shown
to act cooperatively (Singh et al. 2000, Mishra et al, 2002). Regulation of Pax6 gene
expression is also very complex, with alternative splicing and multiple cA-regulatory
elements (Carriere et al. 1993, Reviewed in van Heyningen and Williamson 2002).
Notably, an alternatively spliced form exists, containing an additional exon 5a. The exon
5a containing form of Pax6 has altered DNA binding properties, and a mutation that
increased the ratio of plus 5a to minus 5a transcription caused eye defects (Epstein et al.
1994). Extensive studies have been carried out to identify genes downstream of Pax6,
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paired domain linker al| a^\ a3 PST domain
homeodomain
Figure 5.5: (a) Structure of the Pax6 protein; (b) Expression of Pax6
mRNA in the developing mouse (Reproduced from P. Rashbass).
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and have yielded a large and heterogeneous set of genes, many of which may be specific
to eye development (Michaut et al. 2003, Chauhan et al. 2002, Chauhan et al. 2002b,
Chauhan et al. 2002c, Bernier et al. 2001).
In the developing mouse, Pax6 is expressed in the eye, forebrain, olfactory bulb and
neural tube, indicating an important role in the development of structures other than the
eye (Hogan et al. 1988, Walther and Gruss, 1991, Grindley et al. 1995, Figure 5.5b).
This is reflected in the olfactory bulb hypoplasia, and various subtle CNS defects
observed in the Sey heterozygous mouse (Hill et al. 1991, Collinson et al. 2000,
Collinson et al. 2003). Defects in olfaction and minor CNS defects have also been
observed in humans heterozygous for Pax6 loss of function (Sisodiya et al. 2001).
In humans, homozygous loss of Pax6 function results in a failure of eye development
(anophthalmia) and other CNS defects that cause early neonatal lethality (Glaser et al.
1994). Unlike many proteins a reduction in dose (haploinsufficiency) also causes
defects. Although aniridia is the most prominent defect in humans heterozygous for a
Pax6 null mutation, the eye phenotype caused is extremely heterogeneous, and can
include cataracts, foveal dysplasia, coloboma, lens dislocation, optic nerve hypoplasia,
nystagmus and glaucoma (Jordan et al. 1992, Online Mendel i an In Man record #106210
at http://www.ncbi.nlm.nih.gov/omim). In mouse Sey heterozygotes, as well as reduced
eye size, a variety of defects occur, including coloboma, Peters' anomaly, cataract, and
failure of the eyelids to fuse before birth (Hill et al. 1991, Collinson et al. 2001, Jordan
1992, Thaung et al. 2002). The homozygotes do not develop eyes or nasal structures,
and newborns die because they cannot feed (Hill et al. 1991). It is interesting to note that
overexpression of Pax6 in mice also causes severe eye defects, indicating that eye
development is extremely sensitive to Pax6 dosage (Schedl et al. 1996).
Drosophila ey heterozygotes also have reduced eyes, showing that Pax6 gene dosage is
also important in flies (Quiring et al. 1994). This is significant, as gene dosage
requirements are not always conserved in different model systems. For example, human
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anophthalmia can be caused by heterozygous loss of function of the HMG box
transcription factor SOX2 (Fantes et al. 2003). In the mouse, however, animals
heterozygous for a Sox2 knockout have normal eyes (Avilion et al. 2003). Conservation
of the Pax6 haploinsufficiency phenotype from Drosophila to humans is an important
clue to the mechanism by which Pax6 regulates eye development. There is evidence that
a threshold level of Pax6 protein is required for normal development to proceed (van
Raamsdonk and Tilghman, 2000).
There are two orthologs of Pax6 in zebrafish, termed Pax6a and Pax6b, or Pax6.1 and
Pax6.2. These are thought to originate from a genome duplication that occurred in the
zebrafish lineage (Taylor et al. 2003). Pax6a and b are 82% identical at the cDNA level
and 95% identical at the amino acid level, while the HD and PD are 100% identical
(Nornes et al. 1998). The combined expression pattern of these two genes is very similar
to that observed in the mouse for Pax6 (Krauss et al. 1991, Krauss et al. 1991b, Puschel
et al. 1992, Macdonald et al. 1994, Amirthalingam et al. 1995, Thisse et al. 2001).
Pax6a is strongly expressed in the eyes, forebrain, hindbrain, and neural tube, while
Pax6b is only expressed in the eyes, dorsal diencephalon, pancreas, and part of the
neural tube (Figure 5.6). Only Pax6b is expressed in the pancreas (Biemar et al. 2001)
and early lens placode (Nornes et al. 1998). The Pax6b protein has been shown to have a
higher transactivation activity than Pax6a (Nornes et al. 1998). This shows that,
although it is likely that they share some functions, the Pax6a and Pax6b genes are not
completely redundant.
Further evidence for divergence of function between the two Pax6 genes in zebrafish
comes from studies of the genomic organisation (Dirk Kleinjan and Philippe Gautier).
The exon boundaries in the coding region are conserved, including the alternatively
spliced exon 5a. The intronic sequence is highly divergent, apart from several distinct
regions that share sequence similarity with the tissue-specific regulatory elements
identified in the mouse. (Kleinjan et al. 2001, Reviewed in van Heyningen and
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Figure 5.6: Expression of Pax6 mRNA in zebrafish embryos,
(a-c) Pax6a; (d-e) Pax6b (Reproduced from Thisse et al. 2001).
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between the zebrafish Pax6 genes, while others are only present in one of the homologs,
indicating that the observed differences in expression may result largely from alterations
in regulatory sequence.
Mutations in zebrafish Pax6a or b have not been reported, despite several screens for
mutations that affect eye development (Haffter et al. 1996, Driever et al. 1996, Fadool et
al. 1997, Vihtelic et al. 2002). It may be that Pax6a and Pax6b have sufficiently
diverged in function so that neither can compensate well for the loss of the other.
Complete loss of function mutations, and perhaps most point mutations, may cause very
severe phenotypes with dominant or dominant negative inheritance. Mutations of either
type are often ignored in mutagenesis screens (Haffter et al. 1996). Further evidence for
a very early severe phenotype for zebrafish Pax6 null mutations, comes from a study of
gene silencing by double-stranded RNA (dsRNA) injection. Injection of dsRNA for
Pax6a caused very severe eye and forebrain defects (Li et al. 2000).
There may also be regulatory interactions between the two zebrafish Pax6 genes, similar
to the Pax6 autoregulatory function seen in organisms carrying only one Pax6 gene
(Plaza et al. 1993, Grindley et al. 1995, Kleinjan et al. 2003). Overlapping regulation of
Pax6a and b would amplify the phenotypic effects of a single knockout by affecting the
expression of the other Pax6 orthologue.
5.5 The L224P mutation in Pax6b of sri is predicted to disrupt protein
function
The L224P missense mutation is expected to have a deleterious effect on the function of
the Pax6b protein for several reasons. Amino acid 224 is in the first alpha helix of the
HD (Figure 5.7a). Homeodomains consists of three alpha helices. Where DNA-binding
has been studied, Helix HI and the N-terminal arm connect with the major groove of
DNA in a sequence-specific manner, while the loop between helices I and II contacts the
DNA backbone (Reviewed in D'Elia et al. 2001, Figure 5.7b). Any mutation that
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Figure 5.7: (a) Rasmol diagram of the Drosophila homeodomain
homodimer on DNA. Arrows indicate the lysine that is affected by the sri
mutation (Philippe Gautier); (b) Binding of the HD to DNA (Reproduced
from D'Elia et al. 2001).
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damages the first alpha helix would probably destroy the DNA binding properties of the
HD. The L224P mutation is expected to disrupt the first helix of the HD, as proline lacks
the ability to form the correct bonds to form an alpha helix, earning it the label of "helix
breaker" (Chakrabarti and Chakrabarti 1998). Also L224 is conserved in Pax6 of all
species identified to date, and is one of the most highly conserved amino acids in HD
containing proteins (analysis by Philippe Gautier). Out of 185 HD proteins analysed,
only 11 of the least related proteins have do not have leucine at this position, and none
of the substitutions was for a proline. Of the 60 amino acids in the HD, three showed
complete conservation, 5 were more conserved than L224, and 54 were less conserved.
This amino acid must therefore be very important for HD function.
Missense mutations in Pax6 are relatively rare (54/302 in the Pax6 mutation database).
This is thought to be due to ascertainment bias, as the phenotype caused by missense
mutations is usually distinct from classical aniridia and more heterogeneous than those
observed for loss of function mutations (Hanson et al. 1993, Azuma et al. 2003, Table
5.3). Most of the missense mutations reported are in the PD and PST domain, with only
five in the HD (Table 5.3), possibly because the HD is so important for Pax6 function
that most mutations are lethal. It could also be that the phenotype for missense mutations
in the HD is not usually in the eye. It is unlikely that no phenotype is caused by amino
acid changes in the HD, as it is completely conserved, with no polymorphisms reported
to date in mammals.
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Mutation Domain Phenotype Species Reference
R242T HD, 2na helix Partial aniridia, mother
unaffected carrier
human Morrison et al. 2002
Q255H HD, 3ra helix Aniridia, possibly
spicing defect
human Chao et al. 2000
V256E HD, 3ra helix Cataracts, mild
microphthalmia
mouse Thaung et al. 2002
F258S HD, 3ra helix Optic nerve coloboma,
growth and mental
retardation
human Azuma et al. 2003
S259P HD, 3ra helix Slightly reduced eye
size, irregular pupil
mouse Favor et al. 2001
Table 5.3: Pax6 missense mutations in mammals. Amino acid number refers to the human Pax6
(Genebank reference M93650 at http://www.ncbi.nlm.nih.gov/, Glaser et al. 1992).
Although mutations affecting L224 have not been reported for Pax6, this amino acid is
mutated in two other diseases involving HD containing proteins (Reviewed in D'Elia et
al. 2001, Figure 5.8). Reiger syndrome is an autosomal dominant disorder characterised
by glaucoma, dental hypoplasia and umbilical defects, and is caused by mutations in the
paired-class homeobox protein Pitx2 (Paired-like homeodomain transcription facotor 2).
One family has been identified with a missense mutation that causes the substitution of
glutamine (Q) for leucine. This leucine is at the same position in the first alpha helix of
the homeodomain as L224 (Semina et al. 1996). Dyschondrosteosis is a skeletal
dysplasia syndrome caused by mutations in another paired-class homeobox protein
SHOX (Short Stature Homeobox). A patient was identified with a missense mutation
causing the substitution L132V (Grigelioniene et al. 2000). This substitution is actually
conservative, as valine shares several of the biochemical properties of leucine, such as
polarity and hydrophobicity (Stryer, 1995), but is still causative for the disease. As the
mutation in sri is predicted to cause a larger disruption in protein structure than either of
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Figure 5.8: Homeodomain proteins, showing the leucine that causes developmental
defects when mutated (D'Elia et al. 2001). Part of the first helix of the HD is shown. Amino
acids shared between all three proteins are shown in red. The leucine that is mutated is
highlighted in green.
It is difficult to predict the functional consequences of this mutation, as Pax6 protein
function is extremely complex. It is reasonable to assume that at the very least, the
function of the HD is impaired. It is known that the paired and homeobox DNA binding
domains can act either independently or in cooperation, and that the PD can affect the
DNA-binding properties of the HD (Singh et ol. 2000, Mishra et al. 2002). There is no
evidence, however, for any direct influence of the HD on PD function, so that the PD in
sri may be able to function normally. The HD has been shown to be dispensable for eye
formation in Drosophila (Punzo et al. 2001), although this may be compensated for by
heterodimerisation (Jun and Desplan, 1996, Mikkola et al. 2001) with other Pax
homologues (Jang et al. 2003). Loss of Pax6 HD function in humans results in aniridia
(Azuma and Yamada, 1998, Singh et al. 2001). Conversely in quail and C. elegans
alternatively spliced forms of Pax6 have been identified that lack the PD (Carriere et al.
1993, Zhang and Emmons, 1995). The PD-less isoform is still able to interact with other
HD proteins such as ChxlO and HoxBl (homeo box Bl) (Mikkola et al. 2001). Also
there is enough evidence to show that the HD can interact with other proteins, and
enhance PD function (Planque et al. 2001). Consequently the severity of the effects of
losing Pax6b HD function may vary, depending on the specific interactions of Pax6 in
different tissues.
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5.6 The sri phenotype resembles Pax6 hapioiinsufficiency phenotypes in
mammals
Corroboration for the causative nature of the Pax6b L224 mutation in sri comes from
detailed examination of the eye phenotype. Nearly all aspects of the sri homozygous
mutant phenotype are observed in Sey heterozygous mice. The reason for the mildness
of the sri homozygous phenotype must lie either in the effects of the missense mutation
on Pax6 protein function, or in the presence of the Pax6a orthologue.
The lens is obviously smaller in both 24h sri larvae and Sey mice (Figure 5.9a,b)
(van Raamsdonk and Tilghman, 2000). A delay in the development of pigmentation in
the retinal pigmented epithelium (RPE) can be observed in 72-80 hpf sri embryos,
suggestive of a delay in differentiation of the retina (Easter and Malicki 2002, Figure
5.9c,d). In studies of mouse Pax6 -/- chimaeras it was shown that a reduction in Pax6
gene dosage also delays differentiation of the RPE (Collinson et al. 2003). The optic
fissure is closed by 72 hpf (2 dpf) in WT zebrafish embryos, whereas in sri a fissure
below the pupil is still present in 2-3% of embryos at 3 dpf, and recovers in some
individuals by 5 dpf (Figure 5.10a,b). Non-closure of the optic fissure, or coloboma, is
often found in Pax6 +/- mice, and has been observed in humans heterozygous for Pax6
missense mutations (Hill et al. 1991, Morrison et al. 2002, Chao et al. 2003).
During eye development in both zebrafish and mammals, the lens develops from the
surface ectoderm, and eventually detaches from it. The zebrafish lens detaches from the
cornea by 24 hpf (Easter and Malicki 2002), but in 5 dpf sri embryos, an attachment of
the lens to the cornea is still visible (Figure 5.10c,d). This defect, known as Peters'
anomaly, is also observed in humans heterozygous for Pax6 missense mutations
(Hanson et al. 1994), and in Pax6 +/- mice (Hanson et al. 1994, Collinson et al. 2001).
Irregularity of the cornea is a prominent feature of the sri phenotype. Defects in the
cornea are also found in Sey mice and human aniridia (Jordan et al. 1992, Collinson et
al. 2001, Collinson et al. 2003). Sections show that the lens in both sri and dre is
138
Figure 5.9: Eye defects observed in sri embryos, (a) At 24 hpf the lens is
reduced; (b) WT at 24 hpf; (c) Development of pigmentation in the RPE is
reduced at 72-80 hpf; (d) WT at 72-80 hpf.
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Figure 5.10: Eye defects observed in sri embryos, (a) Delayed closure
of the optic fissure at 3 dpf; (b) WT at 3 dpf; (c) Peters' anomaly at 5 dpf;
(d) WT at 5 dpf.
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disorganised towards the anterior, and there is some discolouration at the centre,
indicative of a cataract (Figure 4.6). Cataracts are also a common feature of human and
mouse Pax6 heterozygotes (Hanson et al. 1994, Hill et al. 1991).
The sri eye phenotype is most likely to be caused by a reduction in size of the lens, as
defects in the cornea and size of the eye can be corrected by rescue of the lens defect in
Pax6 +/- mice (Collinson et al. 2001). Sections of the eyes of larvae show that the retina
is disorganised, but all the cell types appear to be present in their usual location (Figure
5.11). This disorganisation may be the result of a reduction of pressure in the vitreous
fluid caused by lens hypoplasia (Coulombre and Coulombre, 1964). There is no
evidence for the aniridia that is a feature of human Pax6 haploinsufficiency (Hill et al.
1991, Prosser and van Heyningen 1998).
A genera] reduction in the severity of the sri phenotype is sometimes observed between
3 and 5 dpf (5/24 with an obvious improvement), indicating that the delay in optic
fissure closure may be characteristic of a more general delay in eye development,
perhaps due to a delay in lens development (van Raamsdonk and Tilghman 2000).
Surviving adults appear to have normal vision, and sections of the eyes (Allyson Ross)
show no difference compared to the WT (Figure 5.12).
5.7 The pancreatic islet is affected in sri mutant embryos
It has been mentioned that Pax6b is expressed in the pancreas, without Pax6a. Work in
mice has shown that Pax6 is required for differentiation of the glucagon producing alpha
cells. In mice lacking Pax6 the pancreatic islet was disorganised, and almost entirely
lacking in alpha cells, with reduced hormone production in all other islet cells (Sander et
al. 1997, St-Onge et al. 1997). Pax6 has been shown to bind to promoter elements of the
glucagon, insulin and somatostatin genes (Sander et al. 1997). Studies in humans with
aniridia, carrying Pax6 loss of function mutations, may reveal slight intolerance to
glucose (Yasuda et al. 2002).
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Figure 5.11: Variability of the sri phenotype. (a) WT; (b) Mild;
(c) Intermediate; (d) Severe.
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The zebrafish pancreas contains only one islet of Langerhans, which has the same
structure as that seen in mammals, with alpha cells around the outer edge and insulin
producing beta cells inside (Argenton et al. 1999). Pax6a is not expressed during
zebrafish pancreas development, but Pax6b is expressed in the pancreas from 12 somites
(approximately 15 hpf) until at least 24 hpf (Biemar et al. 2001). Therefore it was
expected that loss of Pax6b function in sri could have a similar effect on pancreas
development to that seen in the mouse.
Paraffin wax sections from 5dpf WT and sri -/- embryos were stained for glucagon and
insulin. The islet of Langerhans was clearly visible by glucagon and insulin staining on
the WT (Figure 5.13). The islet can also be clearly recognised by its distinct
morphology, as a clump of cells slightly separated from, but inside the pancreas. Both
the alpha and beta cell populations were disrupted in sri homozygotes, regardless of the
severity of the eye phenotype (6 embryos examined). Disruption of this Pax6b
expressing cell population in sri homozygotes is good evidence that the sri phenotype is
caused by the L224P mutation, and that this mutation destroys the function of Pax6 in
the pancreas, causing a null phenotype.
It is surprising that the sri homozygotes should survive, if they lack a pancreatic islet.
There may be several factors that allow relatively normal glucose homeostasis to occur
in these fish. Strong glucagon staining was observed in oesophagus of every sri embryo
examined, and the stomach of some (Figure 5.14a,b). The glucagon antibody used is
known to cross-react with enteroglucagon in the stomach (Witt et al. 1988, Sigma,
2002), so that up-regulation of enteroglucagon expression may partially rescue the
absence of glucagon. Morphology of the pancreatic islet was occasionally preserved (in
2/3 embryos examined), and some faint insulin staining was observed in some of the sri
embryos, (Figure 5.14c) suggesting that only the alpha cells are completely absent, as
seen in the Pax6 -/- mouse. In a fraction of the sri homozygotes, enough insulin
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Figure 5.13: Markers of the pancreatic islet of Langerhans in WT
embryos, (a) Insulin; (b) Glucagon. Right-hand panels show staining with
secondary antibody only, (c) Double staining. Green, glucagon; Red, insulin;
Blue, autofluorescence. 5 dpf zebrafish embryos. P, exocrine pancreas; I,
islet of Langerhans; S. stomach.
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Figure 5.14: immunohistochemistry of sri embryos, (a) Glucagon
staining in the stomach. Right-hand panel shows staining with secondary
antibody only; (b) Glucagon staining in the oesophagus. Green,
glucagon; Blue, autofluorescence; (c) Double staining showing morphology
of the islet of Langerhans and patches of insulin expression in the islet.
Green, glucagon; Red, insulin. 5 dpf WT embryos.
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expression may remain to allow survival. Somatostatin producing cells may still be
present, as seen in the Pax6 -/- mouse.
Gut and pancreas development in zebrafish is different from that in mammals, so that a
major difference in the regulation of glucagon and insulin is not implausible (Field et al.
2003, Wallace and Pack, 2003). Further evidence for a major difference in pancreas
development in zebrafish, is that a 5 dpf WT embryo stained with an antibody for p48
showed staining only in the islet (Figure 5.15). p48 is a subunit of the PTF1 transcription
factor required for development of the exocrine pancreas in the mouse (Krapp et al.
1998). It is possible that a related protein is expressed in the developing endocrine
pancreas of the zebrafish, while exocrine development is under control of a more
diverged transcription factor complex. There may also be other cells that secrete the
pancreatic endocrine hormones in fish. Insulin is produced in the yolk sac of rat embryos
(Muglia and Locker, 1984), but this would not account for survival of the adult fish. It
has been suggested that insulin is produced outside the pancreas in adult rats
(Rosenzweig et al. 1980), and recently it has been shown in carp that the adipocytes can
secrete insulin (Roy et al. 2003). It is therefore possible that in fish another source can
compensate for the lack of pancreatic insulin.
5.8 Knock-down of Pax6a and Pax6b expression reproduces some aspects
of the sri phenotype
To confirm whether the sri phenotype was caused by the L224P mutation, antisense
oligonucleotide "morpholinos" were used to knock down the expression of Pax6a and
Paxbb. Morpholinos were designed and synthesised by Gene-tools
(http://www.gene-tools.com), to bind the 5'UTR of Pax6a and Pax6b mRNA, and
prevent translation (Figure 5.16). The phenotype caused by the Pax6b morpholino did
not resemble the sri phenotype. For both morpholinos effects were seen in the eyes, with
an irregular retina and pupils, cataracts, and flattened cornea. Defects in formation of the
CNS were present, including mild cyclopia (eyes closer together but not touching).
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a
Figure S.15: (a) p48 staining in the islet of Langerhans of 5 dpf WT
embryos; (b) Secondary antibody only.
148
Pax6a
CRGCGRGGRT RCRflflGGCTG TTGGRRCTRT GCCTCRRRRR GRRTRCTRTR
M P Q K E V Y
Pax6b
TTCRCTGTTT TGCTCGGRRG GGCTCRGGCG GTGGRGCRGR RTGCCTCRRR
>
M P G
Figure 5.16: Antisense morpholinos (green) were designed (by Gene-
tools) to bind the 5'UTR of Pax6a and Pax6b. (Sequence graphics
reproduced from http://www.ncbi.nlm.nih.gov).
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Somite defects were also observed, with disruption of the lateral stripe, a curved body,
and misshapen somites (Figure 5.17). Although Pax6a and Pax6b are not expressed in
the somites, the neural tube is important for the correct induction of somite development
(Miinsterberg and Lassar, 1995, van Eeden et al. 1996). Double knock-down, with
injection of the Pax6a and Pax6b morpholinos together, gave a similar phenotype. The
eye phenotype, however, was sometimes more severe, with a protruding lens in the most
affected embryos (Figure 5.18). This phenotype roughly resembles the protruding lens of
severe sri mutants, but does not appear to be a complete phenocopy.
Unexpectedly, ear defects also occurred in the most severely affected embryos. The ears
appeared to develop normally until 24 hpf, but defects in the number and position of the
otoliths developed by 48 hpf (Figure 5.19a,b). Ear defects may be caused by a lack of
inductive signals from the underlying hindbrain that are necessary for ear development
(Noramly and Grainger, 2002). This type of defect is found in the zebrafish mutant
valentino which has defects in the differentiation of rhombomeres 5 and 6 in the
hindbrain. In this mutant, early ear development also appears normal, but defects occur
after 14 hpf (Mendonsa and Riley, 1999, Figure 5.19c). The ears have not been
examined in Pax6 mutants in mice, and hearing defects have not been reported for
human aniridia patients, so if this phenotype occurs in other organisms it may be
confined to the homozygotes.
The Pax6b morpholino does not appear to be entirely specific. Defects are present in
tissues that do not express Pax6b, including the neural tube and hindbrain. The most
obvious explanation for this is that Pax6b has a regulatory function on Pax6a. It has been
shown in quail and mouse that Pax6 has an autoregulatory function (Plaza et al. 1993,
Grindley et al. 1995), so it is not unreasonable to assume that the two forms of Pax6 in
zebrafish may also have a role in regulating each other. The Pax6b morpholino








Figure 5.17: Phenotypes caused by morpholino injection, (a) Pax6a, 0.5
mM, 5 dpf; (b) Pax6a, 0.5 mM, 5 dpf; (c) Pax6b, 1 mM, 6 dpf; (d) Pax6b,
0.75 mM, 4 dpf; (e) Cataracts, 0.5 mM, 3 dpf; (f) WT, 3 dpf.
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Figure 5.18: Phenotype of Pax6a/Pax6b double morphant. (a) Protruding
lenses; (b) CNS defects; (c) Somite defects. All pictures are of the same
embryo, 0.25 mM Pax6al 0.75 mM Pax6b, 4 dpf.
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Figure 5.19: Otolith defects, (a) Embryos injected with Pax6b
morpholinos, 0.5-1 mM, 2 dpf; (b) WT, 2 dpf; (c) The zebrafish Valentino
mutant also develops otolith abnormalities, as a result of defects in
hindbrain differentiation, 1 dpf (Reproduced from Mendonsa and Riley,
1999).
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A 25-mer morpholino that should not recognise any mRNA in zebrafish was used as a
negative control. This was specific to the beta-globin pre-mRNA in reticulocytes from
thalassaemic humans that carry a splice-generating mutation at position 705. A high
concentration was used (1 mM), but this caused very few defects; 4/51 with a reduced
lens and small characteristically shaped eye, 5/51 with somite defects, and several with
heart oedema, growth retardation or non-inflation of the swim bladder (Figure 5.20). No
defects were observed that resembled those seen with the Pax6a and Pax6b
morpholinos. The fact that the Pax6a and b morpholinos caused the same phenotype,
and have a completely unrelated sequence, shows that the knock-down should be
specific to Pax6.
A rough statistical analysis was carried out, where the average concentration of
morpholino per embryo was calculated, to allow an approximate comparison of the
severity of defects caused by morpholino injection. This showed that for double
knock-down embryos, the frequency of survival and other effects was similar to single
morphants, while the frequency of eye and neural tube defects was increased. The
average concentration for the double morphants is 0.8 if the concentration of both
morpholinos is added together, which is twice the average for Pax6a, and equal to the
average for Pax6b (Table 5.4, Figure 5.20c). The frequency of each of the
morphological defects for double morphants however, is much more than twice that
observed with either morpholino separately. Also the protruding lens phenotype was
never observed for either morpholino alone, even though a complete range of
concentrations was used. This rough analysis suggests that the combined effect of Pax6a
and Pax6b morpholinos together is more than the two separately, so that there is a
synergistic effect when both are injected together. It has already been suggested that
there could be regulatory effects by each Pax6 ortholog on the other. The action of the
non-targeted protein may therefore partially rescue the phenotype of a single
knock-down, by upregulating transcription, so that when both are targeted, the



































Figure 5.20: Defects caused by a non-specific control morpholino.
(a) Characteristic eye abnormalities, 1 mM, 2 dpf; (b) Somite defects, 1 mM,
5 dpf; (c) Frequency of developmental defects in Pax6 morpholino
injected embryos at 4/5 dpf. (Purple, Pax6a\ Red, Pax6b, Cream, double).
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function, this could cause a more severe phenotype in Pax6b morpholino injected
embryos.
n Average % Survival % Unaffected % Eye % Body % Ear % Protruding
conc. (mM) defects defects defects lens
Pax6a 123 0.4 51 32 22 16 18 0
Pax6b 307 0.8 56 33 26 15 22 0
Pax6a/b 252 0.2/0.6 61 26 73 61 50 7
Table 5.4: Frequency of developmental defects in morpholino injected embryos at 4/5 dpf.
The Pax6a and Pax6b morpholinos appear to have a specific effect, causing a phenotype
in tissues that express Pax6. The overlapping phenotypes, however, is suggestive of
regulatory influences or heterodimerisation between the two orthologs. The phenotype
caused by Pax6b knock-down, however, is unlike that seen for sri, suggesting that the
L224P mutation is not a complete loss of function.
5.9 Injection of Pax6b mRNA rescues the sri phenotype
To confirm whether the L224P mutation is causative for the sri mutant phenotype,
Pax6b WT mRNA was injected into sri homozygous mutant embryos. mRNA was
in-vitro transcribed from cloned full-length zebrafish Pax6b cDNA, and a GFP transcript
was also made for co-injection (Dirk-Jan Kleinjan). Several dilutions of Pax6b mRNA
were injected, together with GFP mRNA, into 1 to 4 cell stage embryos. Half of the
embryos from each clutch were not injected, to be kept as a control group. At 24hpf
embryos that did not express GFP were removed. At 3 dpf, each eye was photographed
at the same magnification, and measurements were made of eccentricity, SD radius, area
and the major axis of the pupil and eye (Chapter 2.4, p50). At 5 dpf the sri phenotype
was scored for each group, and the mean severity score was calculated.
When approximately 0.1 pg Pax6b RNA was injected per embryo, the severity score
was 1.1, compared to 1.7 in uninjected embryos, with a t value for the difference of -2.5
(p 0.06, n 19 and 18 respectively). The frequency of coloboma was reduced from 6/38 to
1/36, but not significantly. Measurements at 3 dpf showed a reduction in the major axis,
SD radius and eccentricity of the retina (Table 5.5). This is highly suggestive of a
156
decrease in the severity of the eye phenotype. When 1 pg was injected, the severity score
did not change, although the most of the measurements taken at 3 dpf did. The frequency
of coloboma was slightly increased from 33/138 (24%) to 23/82 (28%). lpg therefore
caused no real change in the sri phenotype. The effects of RNA injection may vary
depending on the concentration used, and these experiments must be repeated to confirm
these findings.
pg RNA n eyes Area P Major axis P SD radius P Eccentricity P
0 36 4540 129.9 8.05 0.498
0.1 38 4602 0.528 130.4 0.85 6.87 0.156 0.45 0.147
0 138 4799 138.6 8.69 0.514
1 82 4935 0.042 144.2 0.004 9.88 0.08 0.567 0.008
pg RNA n eyes Area P Major axis P SD radius " Eccentricity P
0 36 14742 421.51 7.589 0.5311
0.1 38 14585 0.134 414 0.001 6.99 0.008 0.5082 0.013
0 138 13613 387.3 8.06 0.5449
1 82 13917 0 398.7 0 7.63 0.019 0.5344 0.085
Table 5.5: Mean values for measurements taken from 3 dpf injected or control embryos, (a)
Lens, (b) Retina.
5.10 Summary and conclusions
The sri mutation maps to between 29 and 34 cM from the top of linkage group 7, a
region that contains the Pax6b gene. A T>C transition was identified in Pax6b of sri that
is predicted to cause an L224P missense mutation. The L224P mutation is in the first
a-helix of the homeodomain, and is predicted to disrupt the function of at least the HD,
if not the entire Pax6b protein. It is unlikely that the mutation causes a gain of function,
as no phenotype is observed in the heterozygotes, even when treated with radicicol.
The sri homozygous phenotype includes many aspects of the Pax6 heterozygous
phenotype in mammals; reduced lens, delayed pigmentation of the retina, delayed
closure of the optic fissure, irregular cornea, Peters' anomaly, and cataracts.
Immunohistochemistry shows that sri embryos also have a complete absence of
glucagon producing cells, sri homozygotes can survive to adulthood and are fertile. It is
thought that zebrafish have alternative mechanisms for producing insulin and glucagon
that allow the homozygotes to survive.
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The only phenotype observed in sri is in the lens and pancreas, where Pax6b is
expressed without overlapping Pax6a expression. Therefore the absence of defects in
regions where Pax6a is also expressed may be due to redundancy of function between
Pax6a and Pax6b. Heterodimerisation may also play a role in restoring some of the
Pax6b protein function where expression overlaps. Although dominant-negative
phenotypes usually occur due to heterodimeristaion of mutant and WT proteins,
interactions between WT Pax6a and mutant Pax6b might create a dimer with a relatively
normal function. Pax6 is required for lens development in mammals (Ashery-Padan et
al. 2000) but in sri a lens does form, so that some residual Pax6 function must be
present. It is possible that the PD can perform part of the Pax6 function alone in the lens,
but not in the pancreas, as the PD alone has been shown to rescue Pax6 mutants in
Drosophila (Punzo et al. 2001).
Morpholino knock-down experiments also point towards a partial reduction of Pax6b
function by the L224P mutation. The phenotype for a Pax6b knock-down is far more
severe than that observed in sri homozygotes, with severe effects on the brain, neural
tube and eyes. There may be an additional role for the Pax6b PD in regulating the
expression of Pax6a that is unaffected in sri. If sri is caused by a partial loss of Pax6b
function, injection of WT Pax6b mRNA into sri homozygous embryos should restore
the phenotype. Preliminary experiments show that this may be the case. Injection of the
sri mutant mRNA into WT embryos would also test the presence of any
dominant-negative effects.
The buffering of the expressivity of a Pax6b mutation by Hsp90 has important
implications for human developmental eye disease. It will be possible to test Sey mice
for Hsp90 buffering by crossing them to Hsp90 mutants (Voss et al. 2000), or treatment
with inhibitors. It may also be possible to understand the mechanism by which sri is
buffered by identification of proteins that regulate, or are regulated by Pax6, and that





6.1 Summary of findings
This study was undertaken to test the hypothesis that the chaperone protein Hsp90 could
buffer the penetrance or expressivity of mutant eye phenotypes in zebrafish. Embryos
were treated with the Hsp90 inhibitors radieicol and geldanamycin from
mid-gastrulation until 1 dpf, by which time the retina and lens have begun to
differentiate. A concentration was used that caused only transient developmental
retardation and a low level of developmental defects, without induction of a heat shock
response. Detailed analysis of the sri and dre homozygous mutant phenotypes showed
that expressivity is altered by Hsp90 inhibition and heat shock; sri was noticeably
worsened, while dre was slightly improved. The sri mutation was mapped in
collaboration with Ralf Dahm and Robert Geisler (Max Planck Institute for
Developmental Biology Tubingen) and the candidate gene, Pax6b, was sequenced. An
L224P missense mutation was identified in the first alpha helix of the Pax6b HD, which
is predicted to destroy HD function. Absence of glucagon producing alpha cells, and
most insulin producing beta cells in the pancreatic islet of homozygotes, as seen in Pax6
-/- mice, confirms that Pax6b function is disrupted (Sander et ai. 1997, St-Onge et al.
1997).
6.2 Discussion and future work
6.2.1 The expressivity of a Pax6b mutation is buffered by Hsp90
Expressivity of the Pax6b mutant sri is increased by Hsp9Q inhibition. This may occur
due to a direct interaction of Hsp90 with the mutant protein, or indirectly through
interaction with proteins that play a role in eye development, in pathways that affect
Pax6b in some way. Immunoprecipitation of Hsp90 and WT or mutant Pax6 would
reveal whether any direct interaction occurs between Hsp90 and Pax6 in WT or sri
embryos. Identification of any Hsp90 clients with an indirect role will be more
challenging. There are many proteins up or downstream of Pax6 in eye development that
interact with Hsp90 and may influence the sri phenotype if Hsp90 function is
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compromised. Hsp70 and Rafl have already been mentioned (Chapter 4.5, pi 17). It is
unlikely that Hsp70 or other stress induced proteins are involved, as the lens phenotype
in dre is similar to that seen in sri, yet the dre phenotype is not worsened by Hsp90
inhibition or heat shock. Rafl is ubiquitously expressed during development (Storm et
al. 1990), so that any effects of Hsp90 inhibition would have to be very mild for only the
mutant pathway to be affected. The identification of Hsp90 partial loss of function
mutations in two screens for modifiers of Rafl mediated photoreceptor development in
Drosophila, however, shows that a slight reduction in Rafl activity can cause a specific
phenotype in a vulnerable developmental pathway. There is no Rafl mutant in zebrafish,
but quantitative analysis may reveal a reduction in Rafl expression in radicicol treated
embryos.
One other possible mechanism for worsening of the sri mutation after Hsp90 inhibition
is via c-jun NH2-terminal kinase (JNK). It has recently been shown in mice, that JNK
regulates a signalling pathway in eye development consisting of BMP4, Shh and Pax2.
In JNK mutant mice eye development is disrupted, with defects in the lens and
non-closure of the optic fissure. Non-closure of the optic fissure in JNK mutant embryos
has been shown to be due to a reduction in Pax2 expression, by a JNK-BMP4-Shh signal
cascade. The effects in the lens have not been fully investigated, but are thought to be
due to a reduction in c-jun, Pax6 and Sox2 expression (Weston et al. 2003).
Both Hsp70 (Park et al. 2001) and nitric oxide (NO) (Park et al. 2000) negatively
regulate JNK. It is possible that Hsp90 could affect Pax2 expression through interactions
with both Hsp70 and endothelial nitric oxide synthase (eNOS) (Figure 6.1). Hsp90
sequesters Hsp70 and HSF1 in an inactive complex (Guo et al. 2001, Zou et al. 1998). A
concentration of only 5.3 pM geldanamycin in Drosophila larvae is enough to
destabilise this complex, and activate Hsp70 (Auluck and Bonini, 2002). Therefore















Figure 6.1: Mechanism by which Hsp90 may exacerbate the phenotype
caused by the sri mutation. Hsp90 sequesters Hsp70 in an inactive
complex. Hsp90 stimulates production of NO by eNOS, which also inhibits
JNK activity. Hsp90 inhibition has a stronger effect on Hsp70 than eNOS.
Hsp90 inhibition in vivo could therefore release Hsp70, which in turn would
inhibit JNK activity. JNK is required for Pax2 expression in the eye, which
causes closure of the optic fissure.
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Conversely, Hsp9Q has been shown to activate production of NO by direct interaction
with eNOS (Garcia-Cardena et al. 1998), so that Hsp90 inhibition could decrease NO
production and upregulate Pax2 expression. A relatively high concentration of
geldanamycin (1.8 mM, cf. 10 pM in our experiments) is required to reduce eNOS
activity however, so that the principal effect of Hsp90 inhibition may be to activate
Hsp70, with a resultant inhibition of Pax2 expression. A reduction in Pax2 expression in
sri embryos would be expected to increase the severity of the phenotype. The role of
Hsp70 in aggravating the sri phenotype could occur independantly of any
stress-response activity, or its possible role in lens differentiation.
To test the hypothesis that JNK activity is affected by Hsp90 inhibition, the INK
immunocomplex assay used by Park et al. (2000) could be used to assess the effects of
radicicol and geldanamycin on different cell types. The effects of Hsp90 inhibition on
the expression of Pax2, BMP4 (Bone morphogenic protein 4) and Shh in the eyes of
zebrafish embryos could be tested by quantitative analysis. It might also be interesting to
look at levels of Pax6 and Sox2. Expression levels in treated WT embryos might also be
affected, suggesting a mechanism for the reduction in eye size.
Hsp90 inhibition appears to reduce the severity of the dre phenotype. It was expected
that Hsp90 is important in different tissues at different stages in development, so that
selective effects of Hsp90 inhibition on different structures in a phenotype was not
surprising. Hsp90 may stabilise a negative modifier of dre, the effect of which is
reduced when Hsp90 function is compromised. Alternatively, the mutated protein may
be stabilised by Hsp90, and have a gain of function effect while bound to Hsp90, that is
lost when that binding is reduced by Hsp90 inhibitor treatment. Mapping the dre
mutation will allow this mechanism to be investigated more thoroughly. It may also be
informative to section dre embryos, and determine which structures of the eye are most
affected in the embryos with the more severe phenotypes. This could be aided by
immunohistochemistry using antibodies that recognise specific cell types in the eye.
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Examination of treated embryos might show which structures are affected by Hsp90
inhibition.
Hsp90 inhibition may also influence the sri phenotype through modifiers that cause the
variation in expressivity that is observed in untreated embryos. There are many modifier
genes that influence the phenotype of different disease genes (Reviewed in Nadeau,
2001, Haider et al. 2002). It may be possible to select for modifiers that suppress the sri
phenotype by raising mildly affected embryos separately, and selecting for mild
phenotypes for several generations. If the mean severity score decreased with selection,
this would show that genetic modifiers of the sri phenotype were present. If severity of
the mild phenotype line was more affected by Hsp90 inhibition than in unselected lines,
this would show that suppressors of sri were present that were buffered by Hsp90.
Alternatively, selection for a more severe phenotype may cause the accumulation of
modifiers that make the sri phenotype more vulnerable to Hsp90 inhibition. These
modifiers could then be mapped, to allow investigation into the mechanisms by which
Hsp90 affects the phenotype.
6.2.2 The sri mutant phenotype is caused by a Pax6b missense mutation
The L224P missense mutation in Pax6h of sri is expected to disrupt the function of the
HD. Loss of HD function would also affect the PD, which has been shown in some cases
to require the presence of the HD to function efficiently (Singh et al. 2000, Mishra et al.
2002). Lack of a heterozygous phenotype indicates that the mutation is unlikely to have
caused a gain of function. The phenotype caused by a Pax6h antisense morpholino is
more severe than that observed in the sri homozygotes. The most likely outcome of the
L224P mutation is therefore a partial loss of Pax6b protein function.
The sri mutation will add to the study of Pax6b function for several reasons. Lirst, it is a
novel mutation; no mutations in the first alpha helix of the HD have been reported. This
will allow further investigation into the function of the Pax6 HD, both in vivo and in
vitro. Also, in sri homozygotes the retina is relatively unaffected, which will facilitate
164
studies of the role of Pax6 in lens and cornea development. The major advantage of
using zebrafish as a model organism is that development can be followed in vivo, and
GFP can be used to track the activity of important regulatory elements. Lens
transplantation can be carried out in zebrafish (Vihtelic et al. 2001), which will allow
investigation into the aspects of eye development that require Pax6 expression in the
lens.
Viability of the sri homozygotes will allow a long-term study of the effects of the
mutation on eye development, and the apparent recovery of eye morphology. The
mechanism of compensation for loss of glucagon and insulin producing cells in the
pancreas is unlikely to be important for human disease, as a reduction of beta cells
causes fatal type I diabetes in humans (Berne and Levy, 1998). The duplication of Pax6
in zebrafish, and the divergence of regulatory elements between Pax6a and Pax6b have
resulted in the sharing of Pax6 function between the two homologues. The expression of
Pax6b, without Pax6a, in the pancreas and early lens placode is evidence for this.
Redundancy between Pax6a and Pax6b in areas in which they are co-expressed may
contribute to the mildness of the sri phenotype. Division of functions between two Pax6
genes, and redundancy of shared roles, may result in more viable mutations that would
allow examination of different aspects of Pax6 function. The possibility of regulation of
Pax6a by Pax6b and vice versa raises the possibility however, that null mutations in
either gene may not be viable.
Further work could now be carried out to identify the effects of the L224P mutation on
Pax6 protein function. The complete absence of glucagon producing cells in the
pancreas suggests that the HD of Pax6b is essential for the differentiation of these cells.
There may be interactors unique to the alpha cells that require the HD to bind Pax6b.
Some Pax6 function may be preserved in the lens of sri homozygotes, because a lens
forms in most embryos, whereas it is absent in Pax6 -/- mice (Hill et al. 1991). The PD
alone may be able to carry out most of the functions of Pax6b in the lens, or later
expression of Pax6a might suffice to rescue lens development. The small lens in sri
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resembles that of Pax6 +/- mice, in which formation of the lens placode is delayed, so
that fewer lens cells are specified at the onset differentiation, resulting in a reduced lens
(van Raamsdonk and Tilghman, 2000). Markers for the lens placode, such as Sox2
(Kamachi et al. 1998, Thisse et al. 2001) or FoxE3 (Forkhead box E3) (Blixt et al.
2000), could be used to determine whether a similar delay in lens placode formation
occurs in sri homozygotes.
There may be a residual FED function in sri that preserves some of the Pax6b activity in
the lens. Evidence for this comes from studies of the Pax64Neu mutation by Favor et al
(2001). Pax64Nm is an S259P missense mutation in the third alpha helix of the PD, which
causes a milder phenotype than that observed for loss of function mutations.
Electrophoretic Mobility Shift Assays (EMSAs) using a FED binding sequence showed
that while binding of the Pax6 dimer was destroyed by this mutation, the monomer
retained a weak binding activity.
EMSAs as well as luciferase reporter assays in cell culture (Chao et al. 2003) will reveal
whether any residual binding activity remains in the mutated Pax6b protein. Different
PD and FDD Pax6 binding sites should be tested (Singh et al. 2000), to identify whether
the function of one or both of the domains is preserved. The DNA elements that Pax6
binds in the lens and pancreas (Kammandel et al. 1999) should also be tested, to
determine whether binding is more affected in the pancreas than in the lens.
Alternatively, reporter assays could be carried out in cell culture, using lens and
pancreatic alpha cell derived cell lines, to test whether the mutation has different effects
on Pax6 activity in these tissues, due to the presence of different partner proteins. A
study of the binding sites for Pax6a and Pax6b in zebrafish using DNA footprinting
might reveal whether there was any cross-regulatory activity between the two Pax6
homologues. Finally, co-immunoprecipitation of Pax6a and mutant or WT Pax6b will
reveal whether heterodimerisation is important for Pax6 function in WT or sri embryos.
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6.2.3 Hsp90 as a buffer of developmental defects in vertebrates
Although sri could not be described as a cryptic mutation, Hsp90 buffering of a
Mendelian mutation with variable expressivity has important implications for human
disease. There are many human genetic diseases with an extremely variable expressivity.
For example, members of the same family carrying a mutation in Shh can suffer from a
range of defects, from holoprosencephaly, to a single maxillary central incisor (Roessler
et al. 1996). It has been shown that mutations in other genes play some part in this
variability (Ming and Muenke, 2002). If Hsp90 affected the expressivity of diseases
such as holoprosencephaly or MAC under certain environmental conditions, this would
represent a considerable influence on the frequency of severe congenital abnormalities in
populations. If a population was exposed to a low level of an environmental toxin such
as a pesticide, only individuals at a certain stage of development, and carrying
predisposing mutations would be likely to be affected (Figure 6.2). This could explain
the small clusters of MAC reported in rural areas.
Is Hsp90 a buffer of developmental defects in humans?
Further studies should be carried out to determine whether Hsp90 is involved in
modulating mutant phenotypes in humans. To begin with, mouse models of human
disease could be used, and treated with Hsp90 inhibitors. For example, it will be
important to identify whether Pax6 missense mutations are affected in mice, in the same
way as sri. Models of holoprosencephaly could also be used. Also, there are several
amino acid changes that have been identified in human Pax6 studies, and do not appear
to cause a phenotype (Grpnskov et al. 1999, Chao et al. 2000, Chao et al. 2003). These
changes may confer susceptibility to Hsp90 inhibition, and cause eye defects only after
exposure to certain environmental factors during development. This hypothesis could be
tested by creating mice carrying these changes, and treating them with Hsp90 inhibitors.
Mice heterozygous for the Hsp90b null mutation could also be used for these
experiments (Voss et al. 2000), but there is a risk that redundancy between Hsp9Qa and
b could rescue the effects of Hsp90b haploinsufficiency.
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Figure 6.2: Effect of environmental stress on the frequency of
developmental defects in the population. If a population was exposed to an
environmental stress, such as a pesticide, and this inhibits or sequesters
Hsp90, only individuals at a vulnerable stage of development, and carrying
certain mutations may develop defects, leading to a low level of affected
individuals in the population (represented by a red star).
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Once mutations are identified that show a requirement for Hsp90 stabilisation in mice,
the effects of environmental factors on these mutant phenotypes could be studied in
humans. To identify whether stress has occurred during pregnancy, it would be
necessary either to conduct large-scale epidemiological studies based on quantifiable
risk factors, or a detailed medical history. It may be possible, however, to conduct
retrospective analysis to identify a "memory" of severe stress during early development.
Components in the immune system could be identified that remain following this type of
stress (van Eden et al. 2003). Individuals with a seemingly sporadic occurrence of
genetic disease, such as MAC, may be more likely to have been exposed to
environmental stress during development. This would suggest that Hsp90 is involved in
modulating the phenotypic effects of these mutations.
One other way to study the possible requirement for Hsp90 as a developmental buffer in
humans would be to identify Hsp90 polymorphisms in the population, and measure their
effect on development. One study has already identified a nucleotide variant in an adult
that has not affected fitness, but which may confer susceptibility to late-onset disease
(Passarino et al. 2003). Another study has identified Hsp90 polymorphisms in
connection with male sterility (Yamamoto et al. 2002). This study confirms that Hsp90
is important in spermatogenesis, but mutations or polymorphisms that compromise the
buffering capacity of Hsp90 may be more difficult to identify, as the phenotype may be
very pleiotropic.
Prevention of the possible harmful effects of Hsp90 inhibition in humans
If Hsp90 developmental buffering is critical in humans, it will be important to identify
the environmental factors that are particularly damaging to Hsp90 function. Chemicals
that interact directly with Hsp90, or cause induction of the heat shock response are most
likely to compromise Hsp90 buffering. This could be assessed in cell culture or using
zebrafish embryos. One way to identify factors that affected Hsp90 activity would be an
assay that used an Hsp90 client to activate a reporter gene.
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Further investigation of the developmental pathways that are particularly vulnerable to
Hsp90 inhibition would suggest other environmental factors that could influence mutant
phenotypes. Pesticides, industrial chemicals, medicinal drugs, calorific intake, body
temperature and the levels of specific nutrients in the diet may all play a part in
modulating Hsp90 function, either through causing a stress response, or direct inhibition
of Hsp90 activity. Limiting exposure to chemicals that could affect Hsp90 activity, or
regulation of dietary and other lifestyle factors may reduce the risk of developmental
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Appendix A: Zebrafish development
(Summarised from Kimmel et al. 1995, photographs reproduced from ZFIN
developmental staging series).
Time Stage Appearance Comments
4 h 40 min 30% epiboly
e
5 h 15 min 50% epiboly
C






8 h 70% epiboly
o
9 h 90% epiboly
c*









48 h (2 dpf) Long-pec
stage
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Appendix B: Working for t-test (Chapter 2.4)
EtOH

















Experiment Mean 2 SE 2 SE 1
squared
rad56.1
rad56.2
rad 56.3
5739
5534
5062
100
63
113
10000
3969
12769
Mean 5445
Experiment Meanl-
2
rad 56.1
rad56.2
rad 56.3
323
-48
186
Mean difference 461
Sum SE2 41101
VSum SE2 202.733
8
Mean difference/ 2.27391
VSum SE2 8
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